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ABSTRACT 
 
Ramesh Kumar Jha: Computational design of novel proteins for affinity reagents 
(Under the direction of Brian Kuhlman) 
 
Computational protein design is an emerging technology that can pave a way to redesign and 
create novel proteins which have new functions as affinity reagents and protein therapeutics. 
Two approaches have been described to create an affinity reagent for activated form of p21-
activated kinase 1 (PAK1). A good affinity reagent can be developed into a biosensor for 
visualizing the activated form of PAK1 inside cells.  
 In the first approach, truncated auto-inhibitory domain (trunc-AID) from PAK1, 
which is unfolded but binds the activated conformation of PAK1 with an affinity of 4 µM, 
was redesigned for improvement in structure and function. Using a computational approach 
implemented within Rosetta molecular modeling program, a 20-residue helix at the N-
terminus was created in the N-terminus of trunc-AID that had the PAK1-binding region 
conserved. The design, AlmostHelix showed gain in structure and solubility but no 
improvement in binding affinity. 
Another design, PAcKer, where a 16-residue helix was created at the C-terminus of 
the trunc-AID and was inserted in a fluorescent protein (CFP) bound the active conformation 
of PAK1 with an affinity of ~400 nM. CFP-PAcKer did not show any binding to the ‘closed’ 
form of PAK1 making it suitable for a biosensor that can detect only the activated form of 
PAK1 inside cells. 
iv 
A de novo interface design approach was used to create a binding interface on a 
segment from hyperplastic discs protein (‘scaffold’) to bind the active conformation of PAK1 
(‘target’). Using a newly developed protocol DDMI, that is implemented within the Rosetta 
molecular modeling program and uses rigid-body docking, sequence design, and gradient-
based minimization of backbone and side chain torsion angles to design low energy 
interfaces between the ‘scaffold’ and ‘target’, a binder called Spider Roll was designed. 
Spider Roll bound to PAK1 with a modest affinity of 100 µM. Mutagenesis studies 
confirmed that the binding interface was consistent with the design model. NMR studies 
were also consistent with the binding model. Additionally, Spider Roll did not bind the 
‘closed’ PAK1. De novo designed binders that can distinguish between two states of proteins 
have potential use as biosensors.  
 As a future direction for de novo protein interface design, an attempt was made to 
create a metal-mediated interaction between a ‘scaffold’ protein and Ubiquitin as a’target’. 
Metal-mediated interactions have advantage over other non-covalent interactions due to 
strong coordination bond. Experimental testing of multiple designs showed a design (called 
Spelter) bound with low nanomolar affinity to the metal ion, but any metal-mediated 
interaction between Spelter and Ubiquitin was not established. 
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CHAPTER 1 
INTRODUCTION 
Recent development in computational protein design 
The major challenge of computational protein design is to identify a most compatible 
sequence from a huge sequence space that can adopt a given target structure. The size of the 
sequence space is astronomical, for example a 50-residue protein can have as many as 10
65
 
possible sequences. In order to identify ‘a needle in a haystack’ an efficient search algorithm 
and near-to-accurate energy functions are needed.  In the last few decades, efforts from 
several groups have resulted in tremendous progress in this field.
1; 2; 3
 The most striking 
results have been in the de novo design of known and unknown protein folds. Using a fixed 
backbone approach, Dahiyat et al were able to design a completely new sequence for a zinc 
finger fold. The new sequence did not need a zinc ion for tertiary structure and NMR 
spectroscopy showed a compact well-ordered structure consistent with the designed model.
4
 
Other pioneering work by Harbury et al showed a successful incorporation of backbone 
flexibility for a large number of fixed amino acid sequences in the design of α-helical bundle 
proteins with right hand superhelical twist.
5
 Kuhlman et al went a step further by iterating 
between sequence optimization for a fixed backbone and backbone optimization for a fixed 
sequence to generate a globular protein with a novel fold.
6
 Though these successes reveal 
that computational methods can make it possible to search the huge sequence space for the 
protein design, a relatively unaddressed field of protein design is to design functional
2 
proteins from scratch. A functional protein might show a novel interaction with an identified 
‘target’ protein or might catalyze a new reaction. Recent achievements in designing novel 
enzyme catalysis show that the problem has been only lightly touched because the new 
enzymes have 5-7 orders of magnitude lower catalytic efficiency than natural enzymes.
7; 8
 
Another unsolved problem is de novo design of protein-protein interfaces. A novel 
interaction can help design biological tools and protein therapeutics by combining the 
enormous binding affinity and specificity of protein interfaces with rational choice of protein 
functionality. 
Computational protein design for functional improvements 
Published approaches of for improving the function of a protein have been restricted to 
searching small ranges of conformational space through mutagenesis while keeping the 
backbone atoms fixed.  This approach, often called an inverse fold-problem
9
 considerably 
reduces the sequence-structure search space. Several works on specificity and affinity 
modulation have shown impressive results. Using a multi-state design approach to maximize 
the difference in free energy for a target conformation from the undesired competitor 
conformations, Havranek et al was able to design homodimeric or heterodimeric coiled-coils 
with novel specificity motifs.
10
 Joachimiak et al used rigid body transformation to sample 
ensembles of conformations of E7 DNase-Im7 immunity protein and then redesign the 
interface for lower binding energy. Using this approach the authors designed a novel 
hydrogen bonding network with a 300-fold specificity increase for designed pair over the 
design-WT pair.
11
 Earlier the same group used another approach, where a disruptive mutation 
was made on one side of an interface and then compensating mutations done on the other 
side, to design a novel specificity pair in the same system.
12
 Lippow et al used a 
3 
computational procedure for optimization of charge-charge interactions with a single 
mutation and then combined multiple mutants for improved binding affinity of antibodies 
against the respective antigens.
13
 More recently Potapov et al showed that a complete module 
from a protein interface (a protein interface can typically consist of multiple modules, the 
residues across the module do not communicate) can be grafted into an unrelated protein to 
create an interface with similar affinity as the wild-type but a remarkably specific mode of 
binding.
14
  Reynolds et al did a computational redesign of the SHV-1 beta lactamase/beta 
lactamase inhibitor protein pair to improve the affinity by over 100-fold.
15
 Shifman et al  
made eight-fold calmodulin mutant that retained the affinity against one natural target while 
weakened affinity against other wild-type target peptides.
16
 A similar approach was used to 
improve the specificity of calmodulin by 900-fold for one target over another competitor. 
17
 
More recent work by Sammond et al showed that specificity switches can be made by 
creating knob-in-to-hole design and by changing charge-charge interactions to hydrophobic 
interactions.
18
 In all the above successful works, the similarity was in the approach of 
keeping backbone atoms fixed and considering only a small number of mutations during the 
redesign so that the backbone remained unperturbed. Designing a new protein interface in the 
regime of flexible backbone was left unexplored in these previous experiments. 
There is also a high demand for improving the stability of proteins. Most popular 
ways to achieve the goal have been to improve the interactions in the core of the proteins. For 
example, using a rapid computational approach to search for stabilizing mutations, three 
mutations were identified in the core of an enzyme that increased its melting temperature by 
10 C̊ and half life at 50 C̊ by 30-fold.19 Using the same computational program, another 
enzyme was stabilized by more than 5 kcal/mol by introducing only four mutations in the 
4 
core of the protein.
20
 Another complimentary approach to stabilize proteins has been 
introducing new charge-charge interactions on the surface of the protein.
21; 22
 Gribenko et al 
specifically selected polar residues (>50% solvent accessibility) on the surface of two 
different enzymes and mutated them to positive, negative or neutral residues irrespective of 
the charge on the neighboring residues and evaluated the total energy of the system. With a 
small number of substitutions (<5% of total residues), the authors were able to improve the 
stability of the enzyme by >9 ̊C in melting temperature.23 Both these approaches for 
improving the stability of a protein use the simplifying approximations of keeping the 
backbone atoms fixed and/or using a small subset of residues for mutations.   
 Proteins with high solubility are required for high resolution structural studies, 
formulation of protein therapeutics and biochemical characterization of proteins. Molecular 
dynamics approaches
24
 have been used to identify potential residues on a protein which could 
be mutated to less hydrophobic or polar residues
25
 hence reducing the aggregation problem. 
Previous works in de novo design of protein-protein interface 
Computational design of a novel interaction from scratch is still an outstanding challenge. 
The major problems in designing a protein-protein interface are frequent burial of polar 
groups at the interface without any hydrogen-bonding partner and the requirement of 
coupling docking with design while incorporating for backbone movements.
2
 A recent 
success in interface design was achieved by exploring template-backbone orientations that 
would maximize the interaction between the partners. Both the partners were sequence 
optimized.
26
 Using this approach a heterodimer (modest high-micromolar affinity) was made 
from a small monomeric domain from protein G. Though the result was promising, a more 
challenging approach would have been a design with one partner kept fixed in sequence. 
5 
Another more promising result came from grafting key residues from an existing interface 
into a new ‘scaffold’ and then selecting for a good surface complementarity with the target 
protein.
27
 A low nanomolar affinity was achieved with this approach but this method loses 
viability in the absence of known binding partners.  
 The problem of de novo interface design can be simplified by choosing two domains 
that do not interact with each other but do interact with structurally similar partners. The 
major problem of achieving high surface complementarity between the interfaces is solved in 
this case. Using this approach a chimeric homing endonuclease was created by chosing one 
domain each from distantly related endonucleases and then optimizing the interface for 
binding. 
28
  
 Contrary to the modeling-based approaches, directed evolution techniques have been 
very successful in designing novel protein binders.
29; 30
 Novel lower nanomolar maltose 
binding protein binders were selected using phage display with FN3 domain as a starting 
protein
31
 or using ribosomal display technique with an ankyrin repeat based protein.
32
 These 
approaches though have caveats as there is only limited control over choosing the binding 
site. Computational approaches also have an advantage over directed evolution in cases 
where a multi specific binder needs to be designed with no affinity against some other 
‘targets’. 
Rosetta molecular modeling suite 
The Rosetta molecular modeling software package is being developed simultaneously by 
several research groups. It was initially created for structure prediction
33
 and then 
subsequently used for protein docking, loop modeling, high resolution structure refinement 
and protein design.
34
 The structure prediction or protein folding problem has been adequately 
6 
addressed by Rosetta and it has been very successful in predicting tertiary structures of 
sequences less than 100 amino acids. 
35; 36
 The protein design or inverse folding problem, 
where a low energy sequence needs to be determined for a given structure, has been also 
successfully solved using Rosetta. 
6
 The two inversely related problems both need a 
reasonably accurate energy function and a sampling method capable of finding the minima of 
this function. 
Energy function: Rosetta’s full-atom energy function is dominated by 12-6 Lennard-Jones 
potential term. This energy term consists of a favorable attractive term (Eatr) for atoms to be 
close to each other and an unfavorable repulsive term (Erep) to penalize atoms clashing with 
each other.  In order to compensate for the fixed backbone assumption during design, Erep is 
dampened to incorporate for some level of backbone flexibility. The other component of the 
energy function include a Lazaridis-Karplus implicit solvation term (Esol) that favors the 
exposure of hydrophilic residues at the surface and penalizes for the burial of polar groups.
37
 
An orientation dependent hydrogen bonding term
38
 (Ehbond) derived from four parameters 
(distance between the hydrogen and the acceptor atom, angle at the hydrogen atom, angle at 
the acceptor atom and the dihedral angle between given by rotation around the acceptor-
acceptor base bond) between an acceptor and a donor atom allows for the burial of polar 
groups if they are able to make hydrogen bond with another polar group. The residue pair 
potential term (Epair) in Rosetta is a knowledge-based term for scoring electrostatic 
interactions. Charge-charge interactions are very sensitive to the local environment and 
difficult to model. The Epair term is derived from the probability of finding two charged 
residues near each other in the Protein Data Bank (PDB).
39
 Another component of Rosetta 
energy function is the rotamer self energy term (Edun). This term is also a knowledge-based 
7 
term and is derived from the probability of finding a side-chain in a particular conformation 
with certain phi-psi dihedrals of the backbone in PDB. 
40
 The backbone torsion potential 
(Erama) term is also a knowledge-based term, and is related to Ramachandran torsion 
preferences. It is derived from PDB statistics by measuring the probabilities of seeing 
particular amino acids in a secondary structure type (helix, strand and loop) for a particular 
phi, psi angles.
41
 From a weighted linear sum of the above energy terms, an unfolded state 
energy term (Eref) is subtracted.  Eref and the weights of each energy term are calculated to 
best reproduce native sequences for known structures.
42
 
 Rosetta also uses coarse-grained centroid-based representation of side-chains when an 
excessive backbone sampling is required. Optionally it can be used in case of docking to get 
a right orientation of the two chains and relieve any backbone clashes and if it is followed by 
all-atom designs. Rosetta coarse grained energy function is dominated by an environment 
term (Eenv) and pair term (Epair) which respond to solvation and electrostatic effects and are 
based on observed residue distributions in protein structures. Hydrogen bonding is not 
explicitly described as most atoms are missing, but favorable scores are given for the 
formation of β-strands and sheets. Lennard-Jones repulsive term (Erep) which penalizes for 
clashes between the backbone or centroid-based side chains is included while the attractive 
term is included in the form of a radius of gyration (Rg) term which rewards globally 
compact structures.
33
 
 The approximate nature of the energy function is apparent with the absence of 
explicit solvent, long range electrostatics, residual dynamics in the molecule and 
conformational entropy.
34
 
8 
Search algorithm: Rosetta uses the Metropolis Monte-Carlo search algorithm with simulated 
annealing to identify the local minimum of the energy function. It is a stochastic approach 
and useful in searching through a number of local minima. It is non-exhaustive and uses 
discrete set of side-chain conformations (rotamers). The protocol starts with a random initial 
conformation of the system followed by a perturbation such as the substitution of a discrete 
rotamer. Energy is calculated before and after the substitution is made. If the energy of the 
system drops, the change is accepted. If the energy of the system goes up, the change is 
accepted or rejected based on the Metropolis criterion. In brief, the Metropolis criterion 
allows occasional increase in energy so that the system is not trapped in a local minimum. 
For simulated annealing, the search is repeated at lower temperature. This guides the system 
to the local minimum because, at lower temperature, the system is less likely to ‘jump’ out of 
it. A trajectory may consist of thousands of substitutions which is typical for convergence. 
Monte Carlo-plus-minimization strategy
43
 is followed for more rigorous rotamer 
optimization. After each Monte Carlo optimization, torsion angles of the backbone and side 
chains are perturbed from ideality to promote a gradient-based descent of the conformation to 
the local minimum. 
Affinity reagents for biosensors 
For our purpose, an affinity reagent is a protein that can bind any other given protein. An 
affinity reagent can be highly specific and can even distinguish between two different states 
of the ‘target’ protein (Figure 1.1). Affinity reagents have potential uses as therapeutics or for 
creating biological tools. A binder which can preferentially bind to the activated form of a 
‘target’ protein can be an important tool for visualizing spatio-temporal dynamics of the 
protein inside living cells. An affinity reagent derived from the WASP domain
44
 and from the 
9 
Rho binding domain
45
 have been used to create biosensors against the activated form of 
CDC42 and RhoA respectively. These biosensors were very useful in visualizing the timing 
and localization of the above Rho GTPases and understanding their implications on cell 
motility and polarization under different environmental cues. 
 An affinity reagent for a biosensor needs a signal producing moiety  which can either 
be genetically encoded (RhoA biosensor
45
) or can be exogenously attached as a solvent-
sensitive dye (CDC42 biosensor
44
). 
 
  
 
 
 
Figure 1.1. Proposed function of an affinity reagent. (a) The auto-inhibited state of the 
target protein (functional domain in ‘yellow’ and auto-inhibitory domain in ‘green’). A 
biosensor consisting of an affinity reagent is shown in ‘cyan’ and a solvent-sensitive dye is 
shown as blue star. (b) Activation of the target protein results in conformational change and 
dislodging of the auto-inhibitory domain. When the biosensor interacts with the active 
protein, it partially desolvates the dye leading to fluorescence intensity change. 
Model system, goal and design approach 
A good model system against which an affinity reagent is to be designed should show very 
distinct conformations in the activated and inactive forms. An affinity reagent designed 
against the active conformation will then have a very minimal interaction with the inactive 
form and will have the potential to be converted into a biosensor. A good model system 
should also be an important functional protein so that a biological tool against it has more 
impact. A model system for computational design should also have structural information, at 
least one good quality crystal structure. 
10 
 p21-activated kinase 1 (PAK1) is a serine/threonine kinase that undergoes an 
enormous conformational change when an activator like CDC42/Rac binds to it. When an 
activator binds to the auto-inhibited dimer of PAK1, it results in destabilization of the folded 
structure of the auto-inhibitory domain (AID), which is then followed by stabilization of 
activation loop via phosphorylation of T423.
46
 Subsequent phosphorylation on the AID (e.g. 
S144), prevents any simple reversal of activation state (Figure 1.2). 
 
 
 
 
 
 
Figure 1.2. Activation mechanism of p21-activated kinase 1 (PAK1). The kinase domain 
is shown in ‘yellow’ and ‘green’. The autoinhibitory domains are shown in ‘cyan’ and 
‘magenta’. Multistage activation process is initiated by an effector CDC42, which is then 
followed by phosphorylation of several serines and threonines on AID and the activation 
loop of kinase domain. The activation process results in a big conformational change of AID, 
which results in dislodging of the domain from the kinase domain. The region where AID 
was binding is potentially a ‘hotspot’ region for protein-protein interaction and can be 
targeted by affinity reagents. This figure has been adapted from Lie et al. 
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 PAK1 is involved in multiple functions inside the cell. It participates in cell motility 
and cytoskeletal dynamics, transcription though MAP kinase cascades, death and survival 
signaling and cell cycle progression.
47
 Consequently, dysregulation in PAK1 functions have 
implications in pathological conditions and cell transformation. With so many functions to 
perform, we hypothesize that the localization and timing of activated form of PAK1 must be 
tightly controlled. Hence, a biosensor against activates PAK1 will be an important tool to 
offer insights into the already existing knowledge. 
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 Crystal structures of autoinhibited PAK1 (PDB ID: 1F3M)
46
 show the relative 
orientation of the kinase domain and the AID (Figure 1.3). The whole structure consists of 
two kinase domains and two auto-inhibitory domains.   A β-strand swap between the AIDs 
results in a dimerization interface and has been referred to as the CRIB (for CDC42/Rac 
interactive binding region). The activators CDC42/Rac have been proposed to bind at that 
site. Crystal structures of the PAK1 kinase domain, with and without phosphorylation mimic 
in the activation loop also exist (PDB ID: 1YHV, 1YHW).
48
 The two crystal structures have 
similar conformation, which suggest that phosphorylation of the kinase domain may not be 
necessary for attaining the active conformation, though it might be required for activity. The 
information from these structures will be useful for computational modeling.  
 
 
 
 
 
 
 
 
Figure 1.3. Crystal structure of auto-inhibited PAK1. The structure (PDB ID: 1F3M) 
shows two kinase domains (chains C and D) and two AIDs (chains A and B). 
The goal of my research is to create an affinity reagent for the activated form of 
PAK1. The cleft formed by helices (αEF and αG ) is left vacant when PAK1 gets activated 
and is a promising region for protein-protein interaction. I used the PAK1 kinase domain 
12 
from the structure of inactive PAK1 (1F3M, Chain C) as a model for the active PAK1. When 
the crystal structure of kinase domain alone (1YHW) is aligned with the kinase domain from 
the structure of inactive PAK1 (1F3M, chain C), a low backbone RMSD of 1.9 Å is 
observed. Two major differences can be highlighted (Figure 1.4). First, there is a difference 
in relative orientation of the cleft (helices αEF and αG) where AID binds. The structure of 
kinase domain alone, 1YHW, shows the helices are more open. Another difference is seen in 
the conformation of activation loop. 1YHW shows an ordered structure, in 1F3M, the loop is 
disordered. It may be possible that activation loop requires an anchoring to the residue V385 
near the active site. In 1F3M, the inhibitory tail extends to the active site and anchors to the 
residue V385. 
 
 
 
 
 
 
 
 
 
Figure 1.4. Structural alignment of PAK1 kinase domain and kinase domain from auto-
inhibited PAK1. The crystal structure of the PAK1 kinase domain alone  (PDB ID: 1YHW, 
‘magenta) is very similar to the activated kinase domain, but there are two major differences 
from the kinase domain of auto-inhibited PAK1 (PDB ID: 1F3M, ‘yellow’), the absence of 
activation loop in the inhibited kinase domain and rearrangement of αEF and αG helices. 
13 
 In order to design a binder of PAK1 kinase domain, we decided to use the kinase 
domain from 1F3M that showed the conformation of protein in a bound state. The idea was 
that a binder to the cleft in the kinase domain (1YHW) would induce a conformational 
change and bring the helices (αEF and αG) closer to each other which would be consistent 
with 1F3M. Two different approaches were used to design an affinity reagent for PAK1 
kinase domain (Figure 1.5). In one, a naturally occurring binder can be redesigned for 
improved stability, specificity, solubility and affinity. The other approach was de novo design 
of a binding interface on another stable protein (‘scaffold’).  
  
 
 
 
 
 
 
 
Figure 1.5. The two approaches for designing affinity reagents. (a) Redesigning a natural 
binder for improved function. The functional improvement can be in terms of affinity, 
specificity, solubility or stability. (b) De novo interface design approach where a ‘scaffold’ 
protein is redesigned for a novel interaction with a ‘target’ protein. 
The AID binds to the kinase domain in the auto-inhibited state of PAK1. This is the 
binding interaction we will mimic for our biosensor. Under biological condition, an activator 
(CDC42/Rac) binds to the AID and releases it from the kinase domain cleft. The inhibitory 
tail of the AID that extends to the active site and contact with V385 is released and the 
activation loop becomes ordered. If the AID is truncated to remove the inhibitory tail, and 
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residues involved in interaction with the activator removed, the minimal domain should still 
be a good binder of the kinase domain. Using a computational approach in Rosetta, the 
minimal domain was redesigned to improve the features of a good affinity reagent that 
include solubility, specificity, stability and binding affinity. The work has been described in 
chapter 2. 
 Another approach to this problem would be to find a stably-folded protein that is 
structurally similar to the AID, and use it as a seed of an affinity reagent. This similarity is 
necessary because a major concern of de novo interface design is surface complementarity. A 
segment from the hyperplastic discs protein (PDB ID: 1I2T) 
49
 shows a good structural 
homology with the AID and was used as ‘scaffold’ protein for interface design. We 
developed a new protocol for protein interface design in Rosetta.  The protocol was then 
utilized to create an interface on the ‘scaffold’ protein resulting in a modest binder. The work 
has been described in chapter 3. 
Incorporating metal ions in the protein interface as a future direction 
De novo design of protein-protein interaction success can be improved to some extent by 
starting with shape complementarity between the ‘scaffold’ and the ‘target’. The ‘scaffold’ 
protein can have good overall structural homology with a native binder of the ‘target’ or may 
be the region on the ‘scaffold’ to be designed has a curvature complementary with the 
‘target’ surface. The former approach has been used in this work (described in chapter 3). 
The later approach was used in cases of successful published de novo designs.
26; 27
 Another 
approach would be to design specific interacting motifs on the two sides of the interface. This 
can be achieved by designing a ‘knob’ on the ‘scaffold’ protein which is complementary to a 
‘hole’ on the target or vice-versa. Modulating long range interactions have also strong effects 
15 
on association rates. Patches of opposite charge groups on the two sides of interface can also 
play an important role in improving association rates.
50
 The charged groups can even be 
placed in the vicinity of the actual protein interface and still significantly affect the 
association rate.
51
 Another approach would be to create a metal-mediated interaction between 
the interfaces. Apart from contributing to the enthalpy of binding and affecting the 
dissociation rates, metal-mediated interactions have also shown to affect the association rate 
by influencing the alignment of two partners.
52
 
 We used this approach to create a metal (zinc) mediated interaction between ‘target’ 
protein UbC12 (an E2 enzyme in the neddylation pathway) or Ubiquitin and several other 
‘scaffold’ proteins chosen from the protein data bank. UbC12 and Ubiquitin have an exposed 
histidine surrounded by some hydrophobic residues. Since zinc has a tetrahedral coordination 
geometry, where four ligand atoms coordinate with it, the idea was to design three residues 
(consisting of His or Cys) on the ‘scaffolds’ and then the fourth coordination contributed by 
the preexisting ‘target’ histidine.  
 This work discussed in chapter 4, shows partial success in computational design. We 
succeeded in designing a metal binder, but the metal mediated-interaction of two proteins has 
still not been successful. 
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CHAPTER 2 
COMPUTATIONAL REDESIGN OF PAK1 AUTO-INHIBITORY 
DOMAIN FOR A BIOSENSOR 
Abstract 
Computational redesign of the auto-inhibitory domain (AID) of p21-activated kinase 1 
(PAK1) has been described. AID is a 72 residue domain (residues 78-149 of PAK1) remains 
bound to kinase domain of PAK1 in auto-inhibited state. AID-kinase interaction can be split 
onto two distinct modules, first domain-domain interaction between inhibitory switch 
(residues 87-136 of PAK1) and helices αEF and αG of the kinase domain and the second 
peptide-domain interaction between peptide (residues 144-146) and  kinase domain active 
site region (residues 385-387). Multistage activation process of PAK1 results in dislodging of 
inhibitory switch from the kinase, resulting in exposed αEF and αG helices. An affinity 
reagent can specially be targeted to the exposed residues on the helices as they contribute to a 
„hotspot‟ region for PPI. Truncated AID (or WT_IS, residues 83-137 of PAK1) was 
redesigned to have improved properties for a good affinity reagent that can bind the „hotspot‟ 
region and can be developed into a biosensor to detect the activated form of PAK1. The 
binding interface of AID to PAK1 was retained during the redesign process. Three 
generations of designs were tried. In the first case, a β-hairpin was designed, in the second 
case a 20-residue helical region was created for a new N-terminus and lastly 16-residue helix 
was created at the C-terminus of truncated AID. The goal was to improve the structural 
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property, solubility and binding affinity (for the kinase domain, our model for activated form 
of PAK1) of the designed domain. The first design (Hairpin) did not show any advantage 
over truncated AID. The second design (AlmostHelix) showed gain in structure and 
solubility. The final design (PAcKer) when inserted into CFP showed ten-fold improvement 
in binding affinity for the kinase domain. In all designs an extra secondary structure region 
was created in an attempt to improve the functional property. The work is novel in that way 
as no example in literature shows that a new secondary structure sequence can be attached to 
an already existing sequence for improvement in function. 
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Introduction 
Natural proteins are optimized for protein-protein interactions under certain conditions. Most 
often the proteins are evolved to have multiple interactions in order to regulate a signaling 
pathway. Sometimes the proteins can be poorly structured in the absence of the binding 
partner and more often the solubility can impose limitations when the protein is expressed all 
by itself. These possibilities limit the usage of a native protein as an affinity reagent. Our 
ability to rationally design these proteins for improved binding affinity, specificity, stability 
or solubility can result in superior candidates for affinity reagents. In past decade, both 
computational and experimental techniques have resulted in a number of functional 
improvements in proteins. Most of the works carried a series of mutagenesis while 
hypothesizing the structure remained unperturbed. A recent work showed that an extended 
sequence from a structural homologue can be used in a functional protein without 
significantly perturbing the beta-lactamase activity.
1
 Other de novo design work of a loop 
region in a beta-sandwich resulted in an improved stability of the protein.
2
 Some directed 
evolution works with a FN3-type scaffold has resulted in a novel BC or FG loop with a novel 
binding affinity for a „target‟ protein.3 A largely unaddressed protein engineering field has 
been de novo design of a secondary structure region of a protein that would result in a 
functional advantage. 
The auto-inhibitory domain (AID) of p21-activated kinase domain 1 (PAK1, PDB ID: 
1F3M) is a dimer with the formation of a β-ribbon at the interface (Di). The multistage 
activation process of PAK1 starts with a binding of activator to the Di, resulting in a partial
24 
unfolding of the AID and dislodging from the kinase domain.
4
 A series of auto-
phosphorylation at multiple serine sites result in stabilization of the „open‟ state. AID thus 
has specificity for multiple proteins that include the kinase domain of PAK1 and the 
activators, Cdc42 and Rac. The published structures of Cdc42 or Rac with CRIB 
(CDC42/Rac-interactive binding domain) of PAKs
5; 6; 7; 8
 show the involvement of Di 
segment of AID. It also has a propensity to dimerize and undergo structural changes when 
activator protein binds to it.  
In order to use AID as a specific affinity reagent to be developed for biosensor, it 
needs to be redesigned so that it is monomeric, structured, stable and if possible has 
improved binding affinity. AID all alone has partially exposed core residues that reduce the 
solubility. An improvement in solubility will have an added advantage for an affinity reagent. 
The affinity reagents derived from natural binders have been used to create biosensors 
against Cdc42
9
 or RhoA
10
 and were used to visualize spatio-temporal dynamics of the 
activated form of respective protein. 
A recent successful PAK1 biosensor was created  by fusing YFP and CFP at the two 
termini of PAK1.
11
 The biosensor was effective in visualizing the PAK1 activation during 
spreading and motility. Useful information regarding the activation was also gathered. But 
the usefulness of modifying proteins for detections is limited. Modification of the proteins of 
interest for a biosensor can result in perturbed function. Usually the modified proteins also 
need to be overexpressed beyond the endogenous level. More than that the PAK1 construct 
did not have the binding sites of Nck and Grb2 and hence adapter dependent effects could not 
be observed. A more efficient biosensor would sense the endogenous level of activated 
protein.  
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A solvent-sensitive dye based biosensor for Cdc42
9
 and a photoactivable biosensor 
for Rac1
12
 were created earlier. Cdc42 and Rac1 are the activators of PAK1. The biosensor 
of Cdc42 revealed microtubule-dependant activation of the protein in the cell periphery and 
not in the filopodia, activation of Cdc42 in the trans-Golgi compartment and a tight 
coordination between cellular extension and retraction accompanied by the activation of the 
protein. In another case, genetically encoded photoactivatable Rac1 showed cell protrusion 
and ruffling when shone with blue light. PAK1 is also an immediate effector protein of Rac1 
but Rac1 is involved in activation of several other proteins including PAK2-4. A biosensor 
for PAK1 can track the spatial and temporal dynamics of the protein specifically. 
In this work we redesigned AID of PAK1as an independent monomeric protein so 
that it can be used as an affinity reagent. The goal was to retain its kinase binding property, 
remove its inhibitory property and disrupt its affinity for the activators of PAK1. In three 
generations of design a secondary structure sequence was created in an effort to improve the 
functional property of AID as an affinity reagent.   
Results 
AID is not a good affinity reagent for a biosensor 
AID has an inhibitory tail (residues 138-149 of PAK1) that goes into the active site of PAK1. 
The dimerization segment (residues 81-87) is involved in a β-strand swap with other AID 
monomer. In our preliminary experiment to use WT_IS (residues 83-137 of PAK1) alone as 
an affinity reagent for PAK1, we found that the protein did not show strong helical content 
(Figure 2.2) and hence would be unfolded. We hypothesized that the two anchoring events 
(binding of inhibitory tail to the active site and the β-strand swap) along with binding to the 
kinase domain were important to achieve the folded nature of AID as described in crystal 
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structure (PDB ID: 1F3M). Since WT_IS was not properly folded, the exposure of 
hydrophobic core resulted in low solubility at the purification stage and also made it 
susceptible to proteolysis. In an ITC experiment, WT_IS bound to kinase domain with a 
modest affinity of 4 µM. Hence, we decided to redesign the AID for improved structure, 
stability, solubility and binding affinity. 
Design strategy 
We created 3 generations of designs using AID as the starting structure (Figure 2.1 a). In all 
these designs, the goal was to keep the kinase-interacting regions intact (residues 112-134) 
while redesigning away from the interface for improved functional properties. A multiple 
sequence alignment shows that majority of the residues in the range 112-134 that was facing 
the kinase domain were left invariant while some mutations were made on the helix side 
facing away from the kinase to accommodate improved packing with the designed sequences 
(Figure 2.1 b). 
The focus of redesign process was to improve the core of the WT_IS (residues 83-137 
of PAK1). As mentioned earlier, in the absence of the inhibitory tail (residues 138-149), 
WT_IS did not fold properly. A β-strand swap between two auto-inhibitory domains may be 
also responsible for stabilizing the folded conformation of the AID but results in 
dimerization. Hence, in our first approach, we built a β-hairpin between the residue 85 of 
chain B and residue 83 of chain A (PDB ID: 1F3M) to join the two β-strands. Since β-ribbon 
formation was intra- instead of inter- domain, it would inhibit the β-strand swap event 
necessary for dimer formation. Residues 83 and 86 (conserved His across effector proteins of 
CDC42 and Rac) interact with a conserved Asp on the activator protein is a critical 
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interaction for the activation process.
5; 13
 Hence, we removed the two His in our designs. The 
design was named Hairpin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Structural and primary sequence comparison of the models evolved from 
the auto-inhibitory domain (AID, cyan). The focus was to design sequences away from the 
PAK1 kinase domain (yellow surface) interaction region. A β-strand (magenta) is contributed 
by another AID. (a) Three generations of designs are shown as „Hairpin‟, „AlmostHelix‟ and 
„PAcKer‟. The designed structural regions are shown in green. Cyan regions were left largely 
intact except for some point mutations to accommodate the new secondary structure regions. 
(b) Multiple sequence alignment shows the designed secondary structure regions were at N-
terminus or C-terminus while the residues involved in binding to the kinase domain were left 
invariant. 
In a second approach, a 20-residue helical stretch was built in the N-terminus of 
trunc-WT_IS-1 (residues 100-137). The new region in the model packed against the other 
helices of trunc-WT_IS-1 and hence gave a tighter core. Since the new region did not have 
any propensity of forming a β-strand, possibility of inter-domain swap was negligible. 
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Potential residues which interact with the activators of PAK1 were also removed and the 
partially exposed core residues were buried too. The model was called AlmostHelix. 
 In a third approach a 16-residue helical stretch was created at the C-terminus of the 
trunc-WT_IS-2 (residues 87-137). The goal of this approach was to bring the N-terminus and 
C-terminus of the domain close to each other so that it can be inserted into a fluorescent 
protein (for example CFP) between the residues Glu-172 and Asp-173. The approach of 
using a fluorescent protein with a biosensor has been proposed earlier for ratiometric imaging 
to correct for varying cell thickness and non-uniform illumination of the cell.
14
  The new 
helical stretch was also intended to bury the core residues for improved solubility and 
stability. Most of the regions of WT_IS involved in CDC42/Rac interaction or domain swap 
were also removed in this design. The model was called PAcKer (CFP-PAcKer when 
inserted into CFP). 
Design protocol 
We used an iterative structure and sequence optimization protocol
2
 for loop modeling within 
the framework of Rosetta software package.
15; 16
 In brief the protocol uses three- and nine-
residue fragments drawn from the database to build loops of appropriate size. The fragments 
were picked for certain secondary structure propensity. For example, poly-alanine sequence 
was used to collect helical loops from the database and a hypothetical sequence TITNGTIT 
for collecting loops with high β-hairpin propensity. The loop was then redesigned for best 
sequence-backbone compatibility as discussed in Methods section. Distance constraints were 
issued for a proper loop orientation with respect to the rest of the protein.  
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Expression and solubility of the designs 
WT_IS, Hairpin and PAcKer were expressed with an MBP tag while AlmostHelix was 
expressed with a GST tag in E coli. PAcKer inserted into CFP (called CFP-PAcKer) was also 
expressed with a 6×His tag. AlmostHelix expression level in soluble fraction was distinctly 
higher than the other proteins and it was clear from later observations that it was more due to 
the AlmostHelix sequence and not due to vector. Once the protein was cleaved of the GST or 
MBP fusion, and concentrated, AlmostHelix showed no signs of aggregation upto a level of 1 
mM. WT_IS and Hairpin had much lower solubility (< 200 µM) while PAcKer showed an 
intermediate level of solubility. 
Structural properties of the designs 
Far-UV circular dichroism (CD) scan showed WT_IS, Hairpin and PAcKer unfolded while 
AlmostHelix showed a good helical content (minima at 208 nm and 222 nm, Figure 2.2 a). 
Absence of any structure in WT_IS also confirmed that the structural change might be 
induced by the two interactions in which AID is involved, first being the binding to the active 
site of kinase domain using inhibitory tail and the second being the formation of β-ribbon 
using a domain swap with another AID.  
Thermal denaturation of the designs at 222 nm showed AlmostHelix having modest 
cooperative unfolding. This confirmed that the protein is folded but lack of sharp transition 
during thermal denaturation also raised the possibility of a molten globule which would 
suggest a very low difference in total energy between the folded and unfolded states. Hence, 
we performed a far-UV CD scan at a high concentration of trimethylamine N-oxide 
(TMAO), an osmolyte which has been shown earlier to have an ability to force 
thermodynamically unfolded proteins to fold.
17
 We saw a considerable increase in helical 
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content at 0.5 M and 1.0 M of the osmolyte (Supplementary figure S2.1 a). When thermal 
denaturation of AlmostHelix was carried at 222 nm in the presence of 2 M TMAO, we found 
a steeper unfolding transition (Supplementary figure S2.1 b). This confirmed that osmolyte 
can increase the difference in energy between unfolded and folded states and populate the 
folded state. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Structural characterization of computational models and WT domain using 
CD. (a) AlmostHelix shows good helical content. WT_IS, Hairpin and PAcKer are all 
unfolded. (b) AlmostHelix shows very modest cooperative thermal denaturation. 
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Binding affinity and suitability as an affinity reagent 
One of the most important features of an affinity reagent is its binding affinity. A high 
binding affinity ensures improved sensitivity when the affinity reagent is used as a biosensor. 
WT_IS and the designs were tested against PAK1 kinase domain (our model for active 
conformation of PAK1) and PAK1 full length (our model for inactive PAK1). Two 
mutations, V127E and S144E on PAK1 full length ensured AID in an unbound state. This 
mutant PAK1 was a model for „open‟ form of PAK1. Isothermal titration calorimetry 
experiments showed CFP-PAcKer bound to the kinase domain of PAK1 with 10-fold tighter 
binding affinity (gain in binding energy by ~1.4 kcal/mol) than the WT_IS (Table 2.1). We 
hypothesize that the 16-residue rigid linker created on trunc-AID-2 and fusing the new N-
terminus and C-terminus to the CFP reduces the loss in entropy upon binding. Earlier the CD 
scan had confirmed WT_IS to be unfolded and raised the possibility of binding induced 
folding. 
Table 2.1. Biophysical properties of the designs and comparison with the truncated 
AID. The binding affinity was measured for PAK1 kinase domain (model for „active‟ 
conformation). WT_IS corresponds to truncated AID of PAK1 (residues 83-137). 
 
WT_IS Hairpin AlmostHelix PAcKer 
CFP-
PAcKer 
Structured
a No No Yes No ND 
Thermal 
melt
b 
Non-
cooperative 
Non-
cooperative 
Cooperative 
Non-
cooperative 
 
ND 
 
Kd (µM)
c 4 2.6 
1.6 
15 (FP) 
ND 0.4 
a
: Far-UV CD scan 
b
: CD signal at 222 nm as a function of temperature 
c
: Isothermal titration calorimetry.  Fluorescence polarization assay (FP) was used only for 
AlmostHelix 
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This advantage seemed to be absent in AlmostHelix. Though the domain appeared to 
be more structured than WT_IS, there was no advantage in terms of binding energy. One 
possible explanation for this can be made in terms of „locking‟ of the domain in unsuitable 
orientation resulting in loss of conformational sampling. 
CFP-PAcKer bound to PAK1 kinase domain with an affinity of ~400 nM (Figure 2.3 
a). The affinity reagent failed to bind to PAK1 full length (Figure 2.3 b).  The binding 
affinity against PAK1
V127E/S144E
 („open‟ variant) was around 10-fold weaker (Supplementary 
figure S2.2). 
 
 
 
 
 
 
 
Figure 2.3. Isothermal titration calorimetry assays to determine the binding affinities of 
CFP-PAcKer against active and auto-inhibited conformations of PAK1. (a) 208 µM of 
PAK1 kinase domain (model for active conformation) was titrated against 18 µM CFP-
PAcKer. An equilibrium dissociation constant of 400 µM was observed with a molar ratio 
~1. (b) 262 µM PAK1 full length (model for „close‟ auto-inhibited form) was titrated against 
21 µM CFP-PAcKer. The titration failed to show any appreciable heat released or absorbed. 
The data sets were drawn on similar scale for comparison. 
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In order to find out that the binding of CFP-PAcKer to the kinase domain is 
consistent with the hypothesis, a mutation V→E corresponding to residue 127 (based on 
PDB ID: 1F3M) was made on PAcKer. Interaction of the CFP-PAcKer
V127E
 was completely 
disrupted. Similarly a mutation L→E corresponding to residue 470 on PAK1 kinase domain 
(based on PDB ID: 1F3M), also abolished the binding between the two proteins 
(Supplementary figure S2.3). 
CFP-PAcKer derived biosensor (mero-CFP-Packer) specifically ‘lights up’ in the 
presence of PAK1 kinase   domain in vitro 
A mutation K→C was made at the position corresponding to residue 134 (based on PDB ID: 
1F3M) on CFP-PAcKer. A solvent-sensitive merocyanine  dye
17
 was conjugated at this 
position. Since this position was at the interface, a big change in dye environment was 
expected upon PAcKer-PAK1 interaction resulting in alteration of the fluorescence property 
of the dye. The dye has an excitation wavelength of 593 nm and emission wavelength at 620 
nm. The fluorescence property of CFP (excitation at 433 nm and emission at 474 nm) was 
used as a background signal and used for ratiometric expression. The normalized ratio 
((Dye/CFP)Titrant / (Dye/CFP)Buffer)   increased during the titration of PAK1 kinase domain. A 
„one-site binding‟ fit gave a binding affinity of around 600 nM, consistent with the 
equilibrium dissociation constant observed in ITC. Biosensor did not show change in 
normalized fluorescence ratio with full length PAK1 or PAK1 kinase
L40E
 mutant (Figure 2.4). 
When dye was conjugated to CFP-PAcKer
V127E 
there was no change in ratiometric 
fluorescence with PAK1 kinase domain titration (Supplementary figure S2.4).  
 
34 
 
 
 
 
 
 
 
Figure 2.4. Biosensor derived from CFP-PAcKer selectively ‘lights up’ in the presence 
of PAK1 kinase domain. A net gain of ~40% in the normalized fluorescence ratio was 
observed in case of PAK1 kinase domain when it was titrated in 200 nM of biosensor. PAK1 
kinase
L470E
 and PAK1 full length failed to show any appreciable change in fluorescence ratio. 
PAK1
V127E/S144E
 showed an intermediate level of change in fluorescence ratio. A decrease in 
signal at higher titrations may be attributed to prolonged incubation. 
Specificity of CFP-PAcKer derived biosensor 
CFP-PAcKer derived biosensor is expected to „light up‟ against group 1 PAKs (PAK 1-3). 
Since group 2 PAKs (PAK 4-6) are more divergent based on difference in domain 
architecture, we tested CFP-PAcKer against PAK5 kinase domain expressed with a GST tag. 
Isothermal titration calorimetry did not show any appreciable heat absorbed or released 
(Supplementary figure S2.5). CFP-PAcKer conjugated to merocyanine fluorescent dye 
showed very low change in ratiometric fluorescence in the presence of 1 µM of GST-PAK5 
kinase domain (Figure 2.5). A full titration up to 10 µM of GST-PAK5 showed a saturation 
level for the normalized fluorescence different from the saturation level observed for PAK1 
kinase domain (Supplementary figure S2.6). This was not very surprising because the 
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fluorescence signal depends on two different parameters, first how tight the biosensor is 
binding to the „target‟ and second how efficiently the dye gets desolvated. The helices αEF 
and αG where the biosensor was supposed to bind, is more polar in PAK5 than in PAK1 and 
a lower affinity for the biosensor was expected. Different residue composition on the PAK5 
kinase domain interface might result in a different mode of biosensor interaction resulting in 
higher desolvation of the dye environment and a very different fluorescence property of the 
dye. Over all the results confirmed that CFP-PAcKer based biosensor was more selective to 
group 1 PAKs and contributions in signal could be expected from group 2 PAKs if the 
localized concentration reached at micro-molar levels. 
 
 
 
 
 
 
 
 
 
Figure 2.5. CFP-PAcKer derived biosensor gives a poor response with PAK5 kinase 
domain. GST-PAK5 kinase showed a minimal change in normalized fluorescence ratio at 1 
µM of titrant. For a proper comparison, GST at 1 µM or equimolar (1 µM ) PAK1 kinase 
domain and GST were also titrated in biosensor. „Blank‟ refers to 200 nM of biosensor alone.  
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Discussions 
We redesigned the auto-inhibitory domain of PAK1 for improved function as an affinity 
reagent. The focus of the design process was to build the core of that domain so that it can 
attain a tertiary structure. A well-defined structure can have advantage in terms of binding 
affinity (reducing the cost of conformational entropy loss), stability (longer shelf-life), 
solubility (improvement due to less exposed hydrophobics) and resistance to proteolysis. 
Only in case of AlmostHelix, we saw improvement in stability and solubility but that did not 
show any advantage in binding affinity. 
 A 16-residue rigid-linker created in PAcKer that helped to bring C-terminus close to 
N-terminus allowed an efficient insertion of the domain into the CFP. CFP was required in 
the final biosensor for ratiometric expression of signal from the dye. The distance between 
N- and C-terminus of folded minimal AID (WT_IS-2, residues 87-137) is ~22 Å. To insert 
the domain between E172 and D173 would require an ample amount of optimization with 
different forms of linkers. For example just using Gly-Ser (GS) rich linkers, the challenge 
will be to come up with an adequate number of repeats so that the domain does not come too 
close to CFP or get too much strained upon binding to the kinase domain. Very long linkers 
will make the domain very floppy with respect to CFP. A construct (CFP-IS) linking E172 of 
CFP with N-terminus of WT_IS-2 with 3×GS and C-terminus of WT_IS-2 with D173 using 
2×GS did not show any advantage in terms of binding affinity (Supplementary figure S2.7). 
Computational methods helped to design an adequate length of linker in C-terminus of the 
PAcKer. When PAcKer was inserted into CFP, binding induced folding was assisted in the 
same as we hypothesized with the AID, where the two termini of AID were restricted in 
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space, N-terminus formed β-strand swap with another AID and C-terminus tail bound to the 
active site of the kinase domain.  
 It will be interesting to see CFP-PAcKer derived biosensor inside cells. Overall 
change in ratiometric signal with PAK1 kinase domain titration was 40%-50% which might 
still be enough to visualize PAK1 activation inside the cell. Several FRET-based biosensors 
have been shown to reach very similar level of signal change in bound state from unbound 
state.
10; 11
 
Materials and methods 
Loop modeling using Rosetta 
We used loop modeling protocol as described earlier.
18
 The protocol uses Rosetta scoring 
function and fragment insertion methodologies which have been utilized for de novo 
structure prediction.
15
 Using Robetta server
19
, a customized library of fragments was created 
from database of high resolution structure for each three- and nine-residue window in a fasta 
sequence. A pseudo-sequence for the region to be modeled was used to bias the fragments to 
a desired secondary structure. For Hairpin, the query fasta sequence consisted of fixed 
regions (Residues 79-85 Chain B, 88-137 Chain A of PDB 1F3M) and TITNGTIT in 
between the two chunks. For Almost helix the query fasta sequence was poly-alanine 
sequence (20 residues) followed by sequence consisting of residues 100-137 of AID (Chain 
A of PDB 1F3M). In the final case, the query fasta sequence for PAcKer was created using 
sequence 87-137 of AID (Chain A of PDB 1F3M) followed by a 16 residue poly-alanine 
sequence. The fragments corresponding to the region to be modeled were then assembled 
using Monte Carlo simulated annealing technique. Fragment insertions were accompanied by 
a “wobble” operation where the backbone torsion angles (φ, ψ) were perturbed. Monte Carlo 
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minimization protocol
15; 20
 was used to simultaneously optimize sequence for a fixed 
backbone and lowest energy backbone for a fixed sequence. All-atom energy function was 
optimized.
15
 In brief the function is a linear weighted sum of 12-6 Lennard-Jones potential, 
the Lazaridis-Karplus implicit salvation model
21
, an orientation dependent hydrogen-bonding 
potential
22
, backbone-dependent rotamer probabilities
23
, a knowledge-based electrostatic 
energy term
24, amino acid probabilities conditioned on φ and ψ space25and reference energies 
that approximate the unfolded state energy of an amino acid.
26
 
Plasmid constructs, gene synthesis and mutagenesis  
Kinase dead mutants (K298R) of full length PAK1 and PAK1
V127E/S144E
 were cloned in pQE-
80 L (Qiagen) vector. Kinase domain (K298R mutant), residues 250-545 from PAK1 was 
also cloned in pQE-80L vector with an extra sequence 
(MRGSHHHHHHGSDYDIPTTENLYFQC) in N-terminus. The PAK1 kinase
L470E
 mutant 
was made by overlap extension using PCR.
27
 Kinase domain of PAK5, residues 425-718 was 
cloned in pGEX-4T-1 vector with an extra sequence 
(MHHHHHHSSGVDLGTENLYFQSM) in N-terminus. 
WT_IS, Hairpin and PAcKer were expressed were made as an MBP fusion with a 
TEV protease cleavage site and cloned in pQE-80L vector so that 6×His-tag remained at N-
terminus after the expression. AlmostHelix was cloned in pGEX-4T-1 vector so that the 
protein was expressed as GST fusion with a Thrombin cleavage site. CFP-PAcKer was 
cloned in pQE-80L vector with an N-terminus 6×His-tag. 
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Expression and protein purification 
All expressions were carried in BL21(DE3) pLysS cells. The cells were grown upto OD600 
0.6-0.8 and then induced with 0.3 mM IPTG and further grown at 25 °C for 6 h for protein 
expression. The only exception GST-PAK5 kinase was expressed overnight at 20 °C . Cells 
were then disrupted using sonication and resulting lysates were cleared by two rounds of 
centrifugation (18,000 × g) of 20 mins each. The supernatants having PAK1 variants and 
CFP-PAcKer were then purified using a prepacked Ni-NTA column (HisTrap, HP, GE 
Healthcare) followed by an anion exchange step (Source 15Q beads, GE Healthcare). 
WT_IS, Hairpin and PAcKer were purified using Ni-NTA column followed by an overnight 
proteolysis using TEV protease and then again loading the product on Ni-NTA column. The 
second Ni-NTA affinity step removed the 6×His-tagged MBP to give design variants (all 
with an extra GS sequence at N-terminus) as a flow through. Flow through was concentrated 
and then loaded on gel filtration column (Superdex 75, GE Healthcare).  All the design 
variants eluted at similar elution volume (size corresponding to monomer) and appropriate 
fractions combined and concentrated (Amicon Ultra, Millipore). Protein concentration was 
estimated using theoretical molar extinction coefficients and absorbance at 280 nm. CFP-
PAcKer concentration was estimated using CFP absorbance at 433 nm with an extinction 
coefficient of 44000 M
-1
 cm
-1
.  
GST tagged proteins, Almost Helix and PAK5 kinase domain were purified using a 
prepacked column (GSTrap, HP, GE Healthcare). For AlmostHelix, GST tag was cleaved off 
using Thrombin protease (Sigma-Aldrich). Post cleavage, the sample was loaded on anion 
exchange column (HiTrap Q, GE Healthcare). AlmostHelix was collected as a flow-through. 
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GST-PAK5 kinase was further purified using an anion exchange step (Source 15Q beads, GE 
Healthcare). 
Circular dichroism (CD) 
CD data were collected on a Jasco J-815 CD spectrometer. Far-UV CD scans (250-200 nm) 
were carried at a typical protein concentration of 20 µM in a 1 mm cuvette. The temperature 
was maintained at 20 C̊ using a Peltier device. Variable temperature scan was carried 
between 4-96 C̊ while measuring the ellipticity at 222 nm. All ellipticity data were corrected 
with a buffer blank and then converted to mean residue ellipticity. Osmolyte TMAO was 
dissolved in the same buffer and added to the protein. Ellipticity was subtracted from the 
buffer blank containing same amount of TMAO. 
Isothermal titration calorimetry 
The binding affinity of the designed proteins was measured using VP-ITC isothermal 
titration calorimeter (MicroCal, GE Healthcare). The designs were used at concentrations of 
14-21 µM (AlmostHelix at a concentration of 50 µM) in the cell. PAK1 variants were used 
as titrants at a 12-15 fold higher concentrations. The proteins were exhaustively dialysed in 
20 mM Na-Phosphate buffer, pH 7.4, 25 mM NaCl and 5 mM 2-mercaptoethanol (BME). A 
total of 29 titrations of 10 µl each were made. The data was analyzed using Origin50 
software and fitted using a model for „one-site binding‟. 
Fluorescence polarization assay 
The binding affinity of AlmostHelix was also measured using fluorescence polarization 
technique which has been described earlier.
28
 S36C mutation was made on AlmostHelix for 
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conjugation of thiol-reactive fluorescent probe Bodipy(507/545)-iodoacetamide (Molecular 
Probes). Fluorescence polarization assays were carried out on a Jobin Yvon Horiba Spex 
FluoroLog-3 instrument (Jobin Yvon Inc) performed in L-format with the excitation 
wavelength set at 508 nm and emission wavelength set at 545 nm. Bodipy conjugated 
AlmostHelix (in 50 mM Tris-Cl, pH 7.5, 5 mM BME) at a final concentration of 5 µM and 
volume 180 µl was titrated with PAK1 kinase domain (in 50 mM Tris-Cl, pH 7.5, 50 mM 
NaCl, 5 mM BME). 
Conjugation of fluorescent dye to CFP-PAcKer 
Solvent sensitive merocyanine dye
17
 was conjugated to CFP-PAcKer to create a biosensor 
(mero-CFP-PAcKer). Freshly reduced CFP-PAcKer with K→C mutation (at position 
equivalent to 134 in PDB 1F3M) was buffer exchanged to 50 mM Na-Phosphate (pH 7.5) 
using PD10 desalting column (Amersham Biosciences). 3-5 equivalents of mercyanine dye 
dissolved in DMSO (dimethyl sulfoxide) was added to 1 ml aliquot of protein (typical 
concentration 40-100 µM) in an eppendorf tube and immediately mixed by inverting the tube 
several times. The tube was then covered with aluminium foil and left under gentle mixing 
for 2 h at room temperature. The conjugation reaction was then terminated using excess of 
BME (5 µl stock in 1ml reaction mix). Unreacted dye was separated from the conjugated 
protein using PD10 column equilibrated and then eluted with 20 mM Na-Phosphate (pH 7.4), 
25 mM NaCl, 5 mM  BME. Dye-labeled protein concentration was estimated using CFP 
absorbance at 433 nm (ε = 44000 M-1 cm-1). Dye concentration was estimated using dye 
absorbance at 593 nm (ε = 120000 M-1 cm-1). The conjugation efficiency (Dye concentration 
/ CFP concentration) observed was ~100%. 
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Fluorimetric measurement of mero-CFP-PAcKer interaction with PAK1 
Dye-labeled CFP-PAcKer (mero-CFP-PAcKer) in an assay buffer (20 mM Na-Phosphate, 
pH 7.4, 25 mM NaCl, 5 mM BME) was titrated with PAK1 variants so that final 
concentration of mero-CFP-PAcKer was 200 nM and of PAK1 variants ranged between 0-10 
µM. The reaction mix for each titration was made in separate eppendorf tube and incubated 
for 10 mins at room temperature. Readings were taken on Jobin Yvon Horiba Spex 
FluoroLog-3 instrument (Jobin Yvon Inc) where the sample in 3 mm cuvette was excited 
with 433 nm and 593 nm and emission signal captured at 474 nm (CFP signal) and 620 nm 
(merocyanine dye signal) respectively. The readings were taken from lower titrant 
concentration to higher without an intermediate cuvette washing step. Typically data 
accumulation took overall 30 mins from the start of experiment (0 titrant reading) to end of 
experiment (10 µM titrant reading). A normalized fluorescence ratio ((Dye/CFP)Titrant / 
(Dye/CFP)Buffer) was calculated and plotted against titrant concentration. The data was fit 
using SigmaPlot using Michaelis-Menten equation for „one-site binding‟. 
For specificity experiment GST-PAK5 kinase domain was titrated to a final 
concentration of 1 µM. For a proper comparison, PAK1 kinase domain at 1 µM was 
supplemented with 1 µM of GST protein. 
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Supplementary information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemantary figure S2.1. AlmostHelix gains structure in the presence of TMAO. (a) 
Far-UV CD scan of AlmostHelix shows increase in ellipticity at 222 nm as a function of 
TMAO concentration. (b) Thermal denaturation of AlmostHelix at 222 nm shows steeper 
transition and increase in Tm at 2M TMAO confirming gain in conformational stability.  
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Supplementary figure S2.2. Isothermal titration calorimetry assay to determine the 
binding affinity of CFP-PAcKer against ‘open’ form of PAK1. 262 µM PAK1V127E/S144E 
mutant (model for full length „open‟ form) was titrated against 21 µM CFP-PAcKer. The 
binding affinity was weaker than PAK1 kinase domain (model for active conformation).  
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Supplementary figure S2.3. A destructive mutation on either side of proposed CFP-
PAcKer and kinase domain interaction resulted in complete loss of signal in ITC 
experiments. (a) 208 µM of PAK1 kinase domain was titrated in 18 µM of CFP-
PAcKer
V127E
. (b) 208 µM of PAK1 kinase
L470E
 mutant was titrated in 18 µM of CFP-
PAcKer. 
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Supplementary figure S2.4. Mutant biosensor (CFP-PAcKer
V127E
 based) against PAK1 
kinase domain. The normalized fluorescence ratio did not change with titration. 
 
 
 
 
 
 
 
 
 
 
Supplementary figure S2.5. ITC assay to detect interaction between CFP-PAcKer and 
GST-PAK5 kinase domain. 223 µM GST-PAK5 kinase was titrated into 20 µM CFP-
PAcKer. Very weak signal (endothermic) was observed. 
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Supplementary figure S2.6. GST-PAK5 kinase shows poor interaction with the CFP-
PAcKer derived biosensor but shows a different saturation. Since PAK5 kinase was GST 
tagged, equimolar amount of GST was added in PAK1 kinase titration for a better 
comparison.  
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Supplementary figure S2.7. ITC assay to show CFP-IS and PAK1 kinase domain 
interaction. 208 µM of PAK1 kinase domain was titrated into 18 µM of CFP-IS. The 
binding affinity was 1.65 µM with a molar ratio of ~1. 
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CHAPTER 3 
COMPUTATIONAL DESIGN OF A PAK1 BINDING PROTEIN 
Abstract  
We describe a computational protocol, called DDMI, for redesigning scaffold proteins to 
bind to a specified region on a target protein.  The DDMI protocol is implemented within the 
Rosetta molecular modeling program and uses rigid-body docking, sequence design, and 
gradient-based minimization of backbone and side chain torsion angles to design low energy 
interfaces between the ‘scaffold’ and ‘target’ protein. Iterative rounds of sequence design and 
conformational optimization were needed to produce models that have calculated binding 
energies that are similar to binding energies calculated for native complexes. We also show 
that additional conformation sampling with molecular dynamics can be iterated with 
sequence design to further lower the computed energy of the designed complexes. To 
experimentally test the DDMI protocol we redesigned the human hyperplastic discs protein 
to bind to the kinase domain of p21-activated kinase 1 (PAK1).  Six designs were 
experimentally characterized. Two of the designs aggregated and were not characterized 
further. Of the remaining four designs, three bound to the PAK1 with affinities tighter than 
350 µM. The tightest binding design, named Spider Roll, bound with an affinity of 100 µM.  
NMR –based structure prediction of Spider Roll based on backbone and 13Cβ chemical shifts 
using the program CS-ROSETTA indicated that the architecture of human hyperplastic discs 
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protein is preserved. Mutagenesis studies confirmed that Spider Roll binds the target patch on 
PAK1. Additionally, Spider Roll binds to full length PAK1 in its activated state, but does not 
bind PAK1 when it forms an auto-inhibited conformation that blocks the Spider Roll target 
site. Subsequent NMR characterization of the binding of Spider Roll to PAK1 revealed a 
comparably small binding ‘on-rate’ constant (<< 105 M-1 s-1). The ability to rationally design 
the site of novel protein-protein interactions is an important step towards creating new 
proteins that are useful as therapeutics or molecular probes.   
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Introduction 
Protein-protein interactions (PPI) are indispensable for life and irregularities in PPI are 
implicated in many pathological conditions.  The rational design of PPIs is a rigorous test of 
our understanding of molecular recognition and accurate design strategies should allow for 
the creation of novel protein therapeutics, diagnostics and research tools.  Recently there has 
been considerable success in the computational redesign of protein binding affinities and 
specificities.
1; 2; 3
 In these studies, rotamer and sequence optimization protocols have been 
used to identify amino acids that that form good packing interactions, electrostatic 
interactions and hydrogen bonds at target interfaces.  In general, these simulations begin with 
a high-resolution crystal structure of the target interaction.  Considerably more difficult is the 
design of protein interactions for which there is no starting structure.  There have been 
impressive results in the design of new coiled-coils, but these studies rely on known patterns 
of recognition between coiled-coils.
4; 5; 6
 The rational design of novel interfaces between 
arbitrarily chosen proteins remains largely an unsolved problem. 
Recent successes in directed evolution of PPI indicate that even fairly rigid protein 
scaffolds can be remodeled to bind new target proteins.  Ribosome display has been used to 
design ankyrin repeat proteins that bind with high affinity to maltose binding protein and 
aminoglycoside phosphotransferase.
7; 8
 Crystal structures of the complexes show only small 
changes in the conformations of each protein when they dock together. These results suggest 
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a minimal protocol for computer-based interface design: dock the scaffold on to the target 
protein and then redesign the amino acids on the surface of the scaffold to form favorable 
interactions with the target. There are many ways that two proteins can be brought together 
and some orientations are likely to be more designable than others.  The challenge is that 
before redesigning the surface of the scaffold in the presence of the target, it is difficult to 
determine which docked orientation will provide the lowest energy interactions.  Huang and 
Mayo used a reduced representation of amino acid side chains and a fast Fourier-transform 
based docking algorithm to find orientations and positions that maximize potential 
interactions with the target without bringing the proteins too close together.
9
 They used this 
strategy to redesign the β1 domain of streptococcal protein G to form a novel heterodimer 
with a binding affinity of ~300 µM .
10
 In their study, the sequences of both sides of the 
protein interface were optimized and only one docked conformation was explicitly evaluated 
with protein design simulations.   
We have developed a strategy for interface design, called DDMI for dock, design and 
minimize interface, which is based on the premise that it is advantageous to explicitly 
consider many alternate docked orientations and positions. This protocol builds on Rosetta’s 
existing fixed-backbone design subroutine
11
, that, when given a docked conformation for the 
scaffold and target backbones, searches through side chain sequence- and conformation-
spaces to produce a low-energy sequence for the docked conformation. Since we cannot 
know before design begins, which docked conformations will lead to good sequences, we 
must sample many docked conformations. We therefore precede the design step with a 
stochastic, low resolution, rigid-body docking of the two proteins.
12
 Only a single docked 
conformation from the docking stage is passed into the subsequent design phase; however it 
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is rare that two docking trajectories produce the same docked conformation. This initial 
docking phase effectively ensures that the design phase is seeded with a unique docked 
conformation. After docking completes, DDMI iterates between rounds of design and 
gradient-based minimization to settle into a low-energy sequence for the scaffold protein. 
Independent DDMI trajectories settle into dissimilar regions of conformation space, so we 
typically simulate tens- to hundreds-of-thousands design trajectories. Here we use the DDMI 
protocol to design an interaction between the hyperplastic discs protein (HYP) and the kinase 
domain of p21-activated kinase 1 (PAK1).   
Results 
The model system  
We chose kinase domain of p-21 activated kinase 1 (PAK1) as our 'target' protein. The full 
length PAK1 (PAK1-fl) is a multi-domain protein that can switch between an inactive and 
active conformation.  In the inactivated state, the auto-inhibitory domain of PAK1-fl binds 
with the kinase domain of PAK1.  In the activated state, the auto-inhibitory domain is 
unfolded by accessory factors and no longer interacts with the kinase domain.
13
 For de novo 
interface design we targeted a region of the PAK1 that is exposed when the auto-inhibitory 
domain releases.  This is an attractive binding site because it is a known region of protein-
protein interaction and binders that target this region will be sensitive to the activation state 
of PAK1, potentially providing a tool for sensing or controlling PAK1 activity.  The 'target' 
patch is a hydrophobic cleft in the C-terminal domain of the kinase domain between two α-
helices (αEF and αG).  The auto-inhibitory domain of PAK1-fl forms a small helical bundle 
that inserts in the cleft.  As a design scaffold for targeting the PAK1 kinase domain, we used 
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a small helical bundle protein, the Hyperplastic discs protein (HYP, PDB ID: 1I2T),
14
 that is 
similar in size to the auto-inhibitory domain and can fit in the target cleft.  
In a preliminary set of HYP designs we found that it was prone to aggregation when 
redesigned to bind PAK1.  Because we are targeting a hydrophobic cleft on PAK1, the 
redesigned scaffolds typically have additional hydrophobic groups on their surface.  To 
increase the baseline solubility of HYP we selected positions away from the target interface 
for mutagenesis to polar residues.  The mutations, G26E, L37E and L38N are presented in 
some of the designs discussed here.  Additionally, we introduced the mutation A15C to HYP 
to allow for conjugation of the fluorophore Bodipy for measuring changes in fluorescence 
polarization upon binding to PAK1.  Circular dichroism spectra indicate that these mutations 
do not perturb the helical structure of HYP (Supplementary figure S3.1).   
Interface design protocol, DDMI 
To redesign HYP to bind the PAK1 we developed an interface design protocol, called DDMI, 
within the Rosetta molecular modeling suite
15; 16
 (Figure 3.1).  The first stage of the protocol 
was rigid-body docking with a Monte Carlo optimization protocol and a low resolution 
model of the amino acid side chains.
12
 The goal of this stage was to find a plausible docked-
conformation for the two proteins so that they can be designed to bind in this conformation. 
We filter at this stage any docked conformations that show backbone collisions which cannot 
be removed in the design phase. To bias sampling of the scaffold’s conformation to bind 
against the target cleft, constraints were added to the energy function to reward the burial of 
the residues in the cleft. These constraints were then removed after the initial stage of 
docking. Figure 3.2 (a) shows the representative sampling of structures created during ‘dock’ 
stage of the protocol.  
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Figure 3.1. DDMI protocol for protein interface design. Each trajectory starts with rigid-
body docking using a low resolution score function with additional constraints to direct 
predetermined residues to the interface.  A docked conformation with a high score ( binding 
energy >18 REU with a low resolution energy function
16
 ) was rejected (Filter I). When a 
trajectory passes the filter, it goes through 8 rounds of sequence optimization and backbone 
minimization during which LJ-repulsive are ramped upwards and coordinate constraints are 
ramped downwards for 6 rounds. During this process the Lennard-Jones repulsive term of the 
energy function is ramped from 0.85 to 1, whereas the coordinate constraint weight goes 
from 1 to 0.  Designs are filtered before being output based on a binding energy density (<-
0.01 REU/Å
2
) and a maximum number of 4 unsatisfied polar groups at the interface (Filter 
II). 
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Figure 3.2. Conformational sampling in (a) ‘dock’ stage and (b) energy convergence 
during the ‘design/minimize’ stage. In (a) the region in ‘magenta’ depicts the ‘hotspot’ 
region on the target protein. In (b) each line represents an independent trajectory. A drop in 
energy is observed after cycles 11 and 12 during which the coordinate constraints are ramped 
to the final value and are sufficiently weak to let the proteins relieve the strain induced while 
holding the two partners next to each other. 
After docking, iterative rounds of sequence design and structure optimization with 
Rosetta’s all-atom energy function16 were used to find low energy sequence structure pairs.   
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Sequence design was performed with simulated annealing and a rotamer-based representation 
of the amino acid side chains.  Structure optimization was performed using gradient-based 
minimization of rigid-body orientation as well as backbone and side chain torsion angles.  In 
the early rounds of design and minimization, DDMI weakened the repulsive component of 
the Lennard-Jones potential and added coordinate constraints for the backbone Cα atoms to 
prevent the fledgling interface from ‘exploding’: the typical binding energy for the interfaces 
that resulted from the first few iterations was positive. Without the coordinate constraints, the 
minimizer displaced the scaffold from the target, preventing the design of any interface. In 
each iteration, DDMI decreased the weight on the coordinate constraints and increased the 
weight on the Lennard-Jones repulsive term. We found that after eight rounds of sequence 
design and structure minimization most trajectories converged on a local minimum (Figure 
3.2 b). 
Global sampling of conformational space (within the target constraints) was achieved 
by performing independent trajectories that start from uniquely docked complexes.  We 
performed >1 million independent DDMI trajectories with HYP and PAK1.  To assess the 
quality of our designs, we compared our models against 43 naturally occurring protein-
protein interfaces with high-resolution crystal structures (2.3 Å or less, Supplementary table 
S3.1).  We observed three key differences between native interfaces and designed interfaces. 
In the native interfaces, the minimized Rosetta energies correlated strongly with the interface 
sizes (Supplementary figure S3.2).  The average binding energy density, defined as the 
binding energy (in Rosetta Energy Units, REU) per buried surface area (Å
2
) was -0.013 
REU/Å
2
 for the native interfaces (Table 3.1).  Binding energy density was a potent 
discriminator of designed and natural interfaces; most DDMI trajectories resulted in 
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interfaces with poor binding energy densities.  We also observed that native structures had on 
average 4 unsatisfied hydrogen bonds at their interfaces; whereas DDMI models often 
contained many more.  Finally, we observed that naturally occurring interfaces were packed 
more tightly than those produced by DDMI as measured by the SASApack score. The 
SASApack score in Rosetta is derived from examining the difference in the molecular 
surface areas accessible to a 0.5 Å radius probe and accessible to a 1.4 Å radius probe.
17
  
This difference indicates surface area on the protein that is not in contact with either water or 
other protein atoms, and hence reflects the presence of voids that are too small to be filled 
with water.  The score is normalized by the average surface-area difference observed in a 
large set of crystal structures.  A negative SASApack score indicates better packing than 
crystal structures, a positive SASApack score indicates worse packing.  The average 
SASApack score for the set of native interfaces was -1.39 ± 1.29, whereas many of the 
designs had positive SASApack scores. 
Table 3.1. Benchmark scores from native PDBs and the cutoffs used as Filter II during 
simulations. 
 Buried 
surface area 
(Å
2
) 
Polar surface 
area (Å
2
) 
Binding energy 
density (REU/Å
2
) 
Unsatisfied 
polar groups 
SASApack 
score 
Native 
complexes 
2060 ± 675 637 ± 249 -0.013 ± 0.003 4.26 ± 2.44 -1.39 ± 
1.29 
Filter II - - -0.01 4 - 
 
 
These observations motivated the set of filters we incorporated into the DDMI 
protocol.  DDMI discarded designs if their binding-energy density was higher than -0.01 
REU/Å
2
 and if they buried 4 or more polar groups which lacked hydrogen bonding partners. 
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Final selection of the design models was made based on the SASApack score of less than 2.0 
and a minimum buried surface area of 700 Å
2
.  Satisfying all four criteria required 
considerable sampling; less than 1% of the DDMI trajectories passed these filters.  The 
interfaces that were left were of moderate size (900 Å
2 – 1700 Å2).   
Four designs with favorable values for all of the evaluation metrics were selected for 
experimental validation.  Each of them had the c-terminal helix of the scaffold interacting 
with the ‘hotspot’ cleft in PAK1. The main interacting residues on PAK1 were L470, L473 
and Y474. In some cases V436, R438 and R471 were also contributing to the interaction. On 
the scaffold side, the mutations were mainly concentrated on the helix IV (Figure 3.3). 
Residues involved in interaction were mostly hydrophobic consisting of one or two aromatic 
amino acids forming the centre of interactions. Design model 1212 had the greatest number 
of polar residues at the interface, and design model s032 had the fewest polar amino acids at 
the interface (Table 3.2).  
 
 
 
 Figure 3.3. Multiple sequence alignment of the design models selected for experimental 
validation. The interface residues in each case are highlighted.  
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Table 3.2. Computational scores of the selected design models and comparison with a 
native AID-kinase interaction in PAK1 full length. 
Design # of 
mutations 
on 
‘scaffold’ 
# of Dock-
design 
trajectories 
Buried 
surface 
area (Å
2
) 
Polar 
buried 
surface 
area (Å
2
) 
Binding 
energy 
density 
(REU/ Å)
2
 
# of 
unsatisfied 
polar 
groups 
SASApack 
score 
0233 9 3000 1507 286 -0.0118 4  -0.5 
Spider Roll 12 10000 966 174 -0.0152 0 -0.65 
1212 10 
20000 
1500 383 -0.0134 0 2.31 
3533 10 1681 323 -0.0129 3 2.79 
s032
a 
15 320 983 124 -0.0167 0 -3.26 
s037
a 
21 370 1207 288 -0.0173 0 0.72 
Trunc-AID - - 1619 357 -0.0157 2 -0.027 
a
:
 
The models were generated using discrete molecular dynamics on Spider Roll for different 
backbone conformations and the binding interface was designed using DDMI. 
Discrete molecular dynamics (DMD) to sample more backbone conformations 
To study the effect of additional backbone flexibility on the design process, we used discrete 
molecular dynamics
18; 19; 20
 to sample conformational space near one of the designed 
complexes (Spider Roll). From the initial design model, we first performed short DMD 
simulations and picked ten structure snapshots from the simulation trajectory. Next, we 
applied sequence design and minimization (no docking) from the DDMI protocol to the 
snapshots to generate ten new designs, from which the one with the best Rosetta energies was 
selected for the next round of DMD simulation. The iterations were repeated 100 times at 
decreasing simulation temperature to identify low energy designs. Finally we examined all 
the designs that were generated from the iteration protocol, from which we selected two 
designs, named s032 and s037, for experimental verification.  The backbone RMSD between 
s032 and Spider Roll when the target protein was superimposed was 5.36 Å while between 
s037 and Spider Roll the deviation was 4.53 Å. The sequences of the two new designs differ 
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significantly from the initial Spider Roll design. Out of the 21 residue sites being designed, 
the numbers of mutated amino acids are 12 and 18 for s032 and s037, respectively. 
Binding measurements and 'hotspot' mapping  
The six designs were expressed as MBP fusions.  All of them expressed in the soluble 
fraction of E. coli lysate, but 3533 and s032 aggregated when MBP was removed with TEV 
protease.  No further studies were performed with 3533 and s032. The circular dichroism 
(CD) spectra of the designs indicate that the proteins are helical and all of the designs 
exhibited cooperative thermal melts as monitored by the CD signal at 222 nm 
(Supplementary figure S3.1). The four soluble designs were labeled with the fluorescence 
probe Bodipy, and fluorescence polarization was used to monitor binding to PAK1 (Table 
3.3). Spider Roll showed the best binding affinity (Kd = 100 µM) while design model s037 
which was derived from Spider Roll using DMD bound with a dissociation constant of 160 
µM. Model 1212 bound with an affinity of 330 µM and model 0233 failed to show any 
conclusive binding with PAK1.  
Table 3.3. Biophysical characterization of the selected designs 
Design Gel Filtration Far-UV CD 
Scan 
Thermal denaturation FP Assay: K
d
 
(M) 
0233 Monomer Folded Cooperative Poor fit 
Spider Roll Monomer Folded Cooperative 100 
1212 Monomer 
N/D 
330 
3533 Aggregate 
N/D 
s032 Aggregate 
s037 Monomer Folded Cooperative 160 
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To probe if Spider Roll was interacting with PAK1 as designed (Figure 3.4), we 
mutated residues on both sides of the interface that were predicted to contribute to binding.   
 
 
 
 
 
Figure 3.4. Spider Roll – PAK1 model showing the interface residues. On the PAK1 side 
(yellow) L470, R471, L473 and Y474 are the main residues involved in interaction. On the 
Spider Roll side the main contributions come from Y52, A55, G56, I58 and F59. G61 is 
involved in hydrogen bonding with R438. 
Consistent with the design model, the PAK1 mutations L473A and L470E each 
destabilized binding by over 1.4 kcal/mol (Figure 3.5 a). R471A and Y474A also destabilized 
binding by 0.35 and  0.85  kcal/mol respectively. R438, predicted to form a hydrogen bond 
with backbone carbonyls at the C-terminus of Spider Roll, did not have any effect on binding 
affinity when mutated to alanine.  Mutations to residues on Spider Roll that were designed to 
form interactions with PAK1 also weakened binding (Figure 3.5 b).  The point mutations 
F59A and G56E weakened binding by 0.55 kcal/mol. Y52A and A55E mutations had only 
subtle effect with a binding energy cost of approximately 0.4 kcal/mol. A more dramatic 
decrease in binding was observed by combining F59A with G56E (1.4 kcal/mol).  I58A 
mutation, which was predicted to contact PAK1 at the edge of the interface, had very 
R438 
Y474 
L473 
G61 
F59 
G56 
R471 
L470 
Y52 
I58 
A55 
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minimal effect on binding.  The design scaffold (with solubilizing mutations G26E, L37E 
and L38N) had basal level of affinity for PAK1. Taken together the mutational data indicates 
that Spider Roll interacts with the target patch on PAK1, and that the helix IV of Spider Roll 
is involved in binding.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Mutagenesis studies of Spider Roll – PAK1 interface. (a) Effects of Spider 
Roll mutations on Spider Roll – PAK1 interaction in FP assays. HYP mutant (scaffold with 
A15C, G26E, L37E and L38N) did not show any binding. (b) Effects of PAK1 mutations on 
Spider Roll – PAK1 interaction. L470E and L473A mutations showed maximum disruption 
(more than 10 fold weakening in binding). R471A and Y474A had subtle effects while 
R438A did not show any effect on interaction.  
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NMR-based structure prediction of Spider Roll 
In order to structurally characterize Spider Roll as well as its binding to PAK1, we nominated 
Spider Roll mutant I58A, which expressed with a more than two-fold increases yield when 
compared with Spider Roll (see Methods), as a community outreach target of the Protein 
Structure Initiative (PSI) 2 and collaborated with the Northeast Structural Genomics 
Consortium (NESG: http://www.nesg.org) to obtain sequential polypeptide backbone and 
13Cβ chemical shift assignments. The 2D-[15N, 1H] HSQC spectrum21 recorded for Spider 
Roll I58A shows favorable chemical shift dispersion and indicates that the protein is folded 
in solution (Supplementary figure S3.3). Assignment completeness of detectable peaks in the 
2D-[
15
N, 
1
H] HSQC spectrum was 91% (48/53). Polypeptide backbone and 
13Cβ chemical 
shift assignments (Supplementary table S3.2) were obtained for 50 residues and a total of 
81% of the shifts assignable with the selected set (see Methods) of multidimensional NMR 
experiments (i.e. excluding the N-terminal 
15
NH3
+
, the three prolyl 
15
N and the 
13C’ shifts of 
residues preceding prolyl residues). The chemical shifts are in agreement with the location of 
α-helices in the X-ray crystal structure of the design scaffold protein (HYP), except for the 
last ~6 residues of the helix IV (Supplementary figure S3.4, Supplementary table S3.3). The 
shifts were then used to predict the structure of Spider Roll I58A with the program CS-
ROSETTA
22
 (Supplementary figure S3.5). The CS-ROSETTTA  structure is very similar 
structure of design template protein HYP (backbone RMSD = 0.7 Å for helical residues; 
residues 1010-1022, 1026-1036, 1041-1049 and 1051-1065 for 1I2T and residues 2-14, 18-
28, 33-41 and 43-57 for the current structure) which indicates that the re-design of HYP did 
not significantly affect the fold of the protein. 
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The chemical shift indices suggest that the last ~6 residues of the C-terminal helix of 
Spider Roll are frayed in solution. To further investigate the conformation of the helix IV, we 
derived amide proton – amide proton upper distance limit constraints from 3D 15N-resolved 
[
1
H, 
1
H]-NOESY.  The longer distances derived for the C-terminal segment of helix IV 
reflect weaker NOEs (the sequential NOEs between the last 6 residues either overlap or 
disappear), which are consistent with fraying of this segment. All of our designed interfaces 
include a fully intact C-terminal helix that makes close contact with PAK1.  Fraying of the 
helix IV in the unbound state is not inconsistent with a fully folded helix in the bound state, 
but indicates that there will be an additional entropic penalty associated with binding. Hence, 
future improvement of the design of Spider Roll may focus on stabilizing the C-terminal 
segment of helix IV. 
NMR characterization of Spider Roll-PAK1 binding 
The 2D [
15
N, 
1
H] HSQC spectrum
21
 was recorded for Spider Roll I58A was monitored as a 
function of PAK1 concentration. The spectra were recorded at three different molar ratios of 
Spider Roll I58A / PAK1:  231 µM / none, 210 µM / 120 µM, 148 µM / 487 µM). 
Unexpectedly, addition of PAK1 did not induce any perturbation of Spider Roll chemical 
shifts or introduce large broadening of Spider Roll resonances, but lead to a dramatic 
decrease of Spider Roll signal intensities. Specifically, at a PAK1 concentration of 487 µM, 
Spider Roll peak intensities were reduced to <5% of their starting values (Figure 3.6). 
Furthermore, no ‘new’ signals emerged during titration, which could still be attributed to 
Spider Roll bound to PAK1.  This is likely due to the fact that the signals of the 43 kDa 
complex present at a concentration of only ~200 µM are too weak to be detected. Assuming 
for simplicity that both 
1
H and 
15
N line-widths scale linearly with molecular weight
21
, the 
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S/N ratios for Spider Roll in complex with PAK1 are expected to be about 40-fold lower than 
for free Spider Roll.
23
 Since the S/N ratios observed for free Spider Roll are in the range  of 
~20 in the 2D-[
15
N, 
1
H] HSQC spectra, detection of the signal of bound Spider Roll is indeed 
not be expected.  
Furthermore, Spider Roll may bind to PAK1 in different and slowly exchanging 
conformations, a phenomenon which would broaden resonance lines, thereby further 
impeding signal detection for bound Spider Roll. A third scenario which would manifest 
itself by lack of signals for the bound protein would be the formation of aggregates formed 
by the complex.  
To check if the Spider Roll-PAK1 complex aggregates non-specifically, we 
performed size exclusion chromatography with the NMR sample and also ran an SDS page 
gel for an aliquot of the NMR sample. The SDS gel confirmed that the same amount of 
Spider Roll remained in solution as was initially added to the NMR sample, and the size 
exclusion chromatography indicated that the sample was not aggregating:  the only two peaks 
in the chromatogram corresponded to monomeric PAK1 and Spider Roll, which is typically 
observed for proteins with micromolar binding affinities.  Hence, these experiments suggest 
that the absence of NMR peaks from the bound state is indeed likely due to the slower 
overall rotational tumbling of the complex.  
Our NMR data are consistent with the lifetime of the Spider Roll-PAK1 complex 
being much longer than the time required for signal detection (‘NMR chemical shift time 
scale’, around 0.1 s), that is, we obtain as an upper bound for the ‘off-rate’ koff << 10 s
-1
. 
With the dissociation constant KD = koff/kon = 10
-4
 M, we then obtain for the ‘on-rate’ kon << 
10
5
 M
-1
 s
-1
. The on-rate constants for protein-protein binding can vary dramatically (1×10
3
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M
-1
 s
-1
 to 1×10
9
 M
-1
 s
-1
) but are often near 1×10
6
 M
-1
 s
-1
.
 24; 25
  The comparably small on-rate 
constant for Spider Roll could reflect the absence of an effective docking funnel or a 
conformational change that accompanies binding, such as folding of the end of the helix IV 
in Spider Roll. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Normalized Spider Roll I58A HSQC peak volumes as a function of PAK1 
concentration. Titration 1: 231 µM Spider Roll I58A with no PAK1; Titration 2: 210 µM 
Spider Roll I58A with 120 µM PAK1 (green bar) and 213 µM Spider Roll I58A with 124 
µM PAK1 mutant (red bar); Titration 3: 148 µM Spider Roll I58A with 487 µM PAK1 
(green bar) and 150 µM Spider Roll I58A with 490 µM PAK1 mutant (red bar). Positive and 
negative error bars are one standard deviation. 
To validate that the reductions of Spider Roll peak intensities in 2D-[
15
N, 
1
H] HSQC 
are due to   binding to the kinase domain, the NMR titration was repeated for PAK1 mutant 
L470E, which shows reduced affinity for Spider Roll when monitored using fluorescence 
polarization experiments.  Consistently, the changes in peak volume were much smaller than 
those observed with wild type PAK1: at a PAK1 L470E concentration of 470 µM, the Spider 
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Roll I58A peak volumes were still 40%  of their original size (in contrast to <5% for WT 
PAK1) (Figure 3.6, Supplementary figure S3.6). 
Does Spider Roll adopt multiple docked positions when binding PAK1?  
Both the NMR data and mutational data indicate that Spider Roll binds the target cleft on 
PAK1, but they do not rule out the possibility that it can adopt alternative docked orientations 
when bound to PAK1.  To further examine this possibility we used Rosetta to perform 
protein-protein docking simulations with Spider Roll and PAK1.  In these simulations, Spider 
Roll was constrained to be near the target binding site, but was allowed to adopt alternative 
orientations relative to PAK1.  Many independent trajectories were used to probe the energy 
landscape and the energies of the various models were plotted versus RMSD to the target 
conformation.  We identified two clusters of low energy structures (Figure 3.7 a).  The lowest 
energy cluster was centered on the design model, but the second cluster packed helix IV in a 
direction that was orthogonal to the design model (Figure 3.7 b, c).  The mutational data does 
not strongly distinguish between the two alternatives.  The mutations that have the strongest 
effect on binding energy are buried in both sets of models (Table 3.4) as calculated by the 
NACCESS program.
26
 
Table 3.4. Buried solvent accessible surface area (SASA) of the interface residues in 
Spider Roll-kinase complex in two alternate docked positions (Figure 3.7). NACCESS 
program
26
 was used to calculate the absolute SASA of each interface residue in the complex 
and then subtracted from SASA of each residue in the independent chains to give buried 
SASA. 
Interface residue R438 L470 R471 L473 Y474 Y52 A55 G56 I58 F59 
Low RMSD (Å
2
) 81 104 43 50 98 102 52 22 53 135 
High RMSD (Å
2
) 110 135 49 61 67 125 35 16 27 113 
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Figure 3.7. Presence of two competing states in Spider Roll – PAK1 model.  (a) Energetic 
‘dock’ funnel shows the presence of two competing states, designated by two stems of the 
funnel. (b) Orientation of interface residues in low RMSD confirmation (PAK1 in yellow and 
Spider Roll in cyan). (c) Orientation of same residues in high RMSD state (PAK1 in yellow 
and Spider Roll in magenta). Ineffectiveness of I58 and R438 mutations (in Figure 3.5) is 
consistent with the State 2 where there is no involvement of these residues in interaction.  
Spider Roll binds preferentially to the activated form of full-length PAK1 
In its inactive form, full-length PAK1(PAK-fl) forms a closed conformation in which an 
autoinhibitory domain binds to the same cleft in the kinase domain that we have targeted 
with Spider Roll.  PAK1 can be opened by introducing mutations in the autoinhibitory 
elements (V127E, S144E) that weaken affinity for the kinase domain.  Using fluorescence 
polarization we measured the affinity of Spider Roll for WT PAK-fl and PAK1-fl with the 
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mutations V127E and S144E.  Spider Roll showed no binding with WT inactive PAK1, but 
bound the activating mutant with an affinity of 200 µM (Figure 3.8). 
 
 
 
 
 
 
 
Figure 3.8. Spider Roll distinguishes between ‘closed’ and ‘open’ full-length PAK1 
(PAK1-fl). Spider Roll binding titrations with PAK1 V127E/S144E mutant (PAK1-fl 
mutant, model for full length ‘open’ form) and PAK1-fl (inactive ‘closed’ form). 
Discussions 
The computational design of novel protein-protein interfaces with high specificity and 
affinity remains an unsolved problem.  Here we have explored the effectiveness of an 
interface design protocol that includes rigid-body docking, rotamer-based sequence design 
and minimization of side chain and backbone torsion angles. With this protocol we were able 
to design small interfaces between HYP and PAK1 (ΔSASA ~1000 Å2) that had calculated 
binding energies comparable to naturally occurring interfaces of the same size.  Design 
models with interfaces larger than 1500 Å
2
 either exhibited inferior packing, buried too many 
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unsatisfied hydrogen bonding groups or had significantly worse binding energy densities 
than native complexes. These results suggest that more extensive backbone sampling and/or 
screening of multiple scaffolds will be needed to build larger interfaces with tight packing 
and good hydrogen bonding.   
Three of the six experimentally characterized designs bound PAK1. Spider Roll, 
which was the tightest binder, bound PAK1 with an affinity of 100 µM. For comparison, the 
truncated autoinhibitory domain (trunc-AID, residues 83-137) from PAK1 binds to the same 
target cleft with an affinity of 4 µM (unpublished data). Even though the AID is smaller (55 
residues) than the HYP scaffold (61 residues), the interface between trunc-AID and PAK1 is 
larger than the Spider Roll interface, 1620 Å
2
 versus 970 Å
2
. The calculated binding energy 
for the trunc-AID-PAK1 complex (after minimization with Rosetta) is -25 REU (-0.016 REU 
/ Å
2
) compared to -15 REU (-0.015 REU / Å
2
) for Spider Roll. The more favorable energies 
achieved by the AID domain (experimental and computational) may reflect the evolution of 
this domain to have a backbone conformation suitable for binding the PAK1 kinase domain, 
while the backbone conformation of HYP has not been optimized for binding PAK1. 
Mutation studies and NMR studies do not rule out the possibility that Spider Roll 
samples multiple docked positions when bound to PAK1.  This may partially reflect the 
hydrophobic nature of the designed interface; the buried SASA is 82% nonpolar.  For native 
protein-protein interfaces (Supplementary table S1) the average is 69% nonpolar (or 31% 
polar, Table 1).  Polar interactions can increase specificity because of the strong distance and 
orientation dependence of hydrogen bond energies.  The interfaces designed in this study 
were predisposed to be hydrophobic because of the hydrophobic nature of the target cleft; 
however, several polar residues on PAK1 surround the cleft. The AID domain forms 
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hydrogen bonds with N468 and R471 on PAK1, while these residues are left solvent exposed 
in the Spider Roll design. Designing multiple hydrogen bonds across a protein interface is 
challenging because optimizing one bond with rigid-body or backbone perturbations is likely 
to disrupt the surrounding bonds.  
Spider Roll binds to the open state of full length PAK1 but does not bind to the closed 
inactive form of the protein. Affinity reagents that distinguish the activation state of target 
molecules are useful starting points for creating biosensors. Typically the proteins are 
modified with fluorescent groups (chemically or genetically encoded) that change their 
fluorescent properties when the affinity reagent binds the target. Our results suggest that 
computational design may be one route for identifying novel affinity reagents.  However, to 
have useful biosensors it will be necessary to have binding affinities tighter than 100 µM.  A 
potential strategy for achieving this goal is to combine computational design with affinity 
maturation via techniques such as phage or yeast display. This strategy was recently used to 
improve the rate of catalysis by a computationally designed enzyme.
27
  
Materials and Methods    
Computational methods 
Rosetta 
Our interface design protocol, DDMI, is described in the Results section and Figure 3.1. It 
was implemented within the Rosetta molecular modeling program.
15; 16
 A single trajectory 
consists of a ‘dock’ stage followed by several iterations of ‘design’ and ‘minimization’ 
stages. The ‘dock’ stage involves a low resolution rigid body Monte Carlo search,12 where 
the side chain of each residue was represented as one bead placed at centroid position of the 
side chain. We applied constraints so that the ‘scaffold’ remains close to and packs one or 
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more of L470, L473 and Y474 residues on the ‘target’. A trajectory satisfying the constraints 
was designed with 8 iterations of sequence and backbone optimizations, similar to protocols 
described earlier.
28
  
Sequence optimization was done using Monte-Carlo simulated annealing protocol
11; 
29
 which optimized the total energy of the complex. The all-atom energy function in Rosetta 
is a linear weighted sum of 12-6 Lennard-Jones potential, the Lazaridis-Karplus implicit 
solvation model
30
, an orientation-dependant hydrogen bonding potential
31
, backbone-
dependent  rotamer probabilities
32
, a knowledge-based electrostatic energy
33
, amino acid 
probabilities conditioned on φ and ψ space34 and reference energies that approximate the 
unfolded state energy of an amino acid. 
11
 
Binding parameters calculation    
The binding energy of a complex was calculated by subtracting the individual Rosetta 
energies of the chains from the total energy of the complex. Total buried surface area at the 
interface was similarly calculated by taking the difference in SASAs between the bound and 
unbound states. The number of buried unsatisfied hydrogen bonding groups was determined 
by counting the number of polar groups at the interface which were fully buried yet lacked 
hydrogen bonding partner. The side chain rotamers were left in the same conformations as in 
the complex when the calculations were made. The interface SASApack scores were reported 
as the average per-residue SASApack score for those residues within 5 Å of atoms on the 
opposite chain. 
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Discrete molecular dynamics 
DMD is a flavor of molecular dynamics simulation (MD) approach.
18; 19; 20
 Unlike traditional 
MD which uses continuous physical force field, in DMD, the interaction between two atoms 
is described by a simplified step-wise potential. For step-wise potentials, the derivations are 
zero between the potential steps, and the integrations can be ignored except when the two 
atoms go across the steps wall (collision events). The space and time of the collision events 
can be analytically calculated based on previous positions and velocities of the two atoms. 
The new velocities of the atoms after the collision can also be calculated based on laws of 
conservation of energy, momentum, and angular momentum. The system evolves by 
calculation and sorting of further collision events. Compared with traditional MD that is 
driven by numerical integration over fine time steps, DMD is driven by collision events and 
is more efficient since it allows larger integration time steps in average. Extra efficiency is 
also gained by applying fast event sorting and updating algorithms. Although the actual 
speed up of DMD compared to traditional MD varies from system to system, it can reach 3–
10 orders of magnitude.  
Experimental methods 
Plasmid constructs, gene synthesis and mutagenesis  
Kinase dead mutant (K298R) of full length PAK1(PAK1-fl) and PAK1 V127E/S144E  
(PAK-fl mutant) were cloned in pQE-80 L (Qiagen) vector. Kinase domain (K298R mutant), 
residues 250-545 from PAK-fl (here referred to as PAK1), was also cloned in pQE-80L 
vector with an extra sequence (MRGSHHHHHHGSDYDIPTTENLYFQC) in N-terminus. 
The PAK1 mutants were made by overlap extension using PCR.
35
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Constructs for protein designs and Spider Roll mutants  (from here referred as 
designed variants) were made as an MBP fusion with a TEV protease cleavage site and 
cloned in pQE-80L vector so that 6×His-tag remained at N-terminus after the expression . 
The genes for designed variants  were synthesized using a gene synthesis protocol
36
 where 
the codons were optimized for bacterial expression. 
Expression and protein purification 
All expressions were carried in BL21(DE3) pLysS cells. The cells were grown upto OD600 
0.6-0.8 and then induced with 0.3 mM IPTG and further grown at 25 °C for 6 h. Cells were 
then disrupted using sonication and resulting lysates were cleared by two rounds of 
centrifugation (18,000 × g) of 20 mins each. The supernatants of PAK1-fl and PAK1 variants 
were then purified using a prepacked Ni-NTA column (HisTrap, HP, GE Healthcare) 
followed by an anion exchange step (Source 15Q beads, GE Healthcare) and gel filtration 
chromatography (Superdex 75 or Superdex 200, GE Healthcare). Designed proteins (referred 
to as design variants) were purified using Ni-NTA column followed by an overnight 
proteolysis using TEV protease and then again loading the product on Ni-NTA column. The 
second Ni-NTA affinity step removed the 6×His-tagged MBP to give design variants (all 
with an extra GS sequence at N-terminus) as a flow through. Flow through was concentrated 
and then loaded on gel filtration column (Superdex 75, GE Healthcare). All the design 
variants eluted at similar elution volume (size corresponding to monomer) and appropriate 
fractions combined and concentrated (Amicon Ultra, Millipore). Protein concentration was 
estimated using theoretical molar extinction coefficients and absorbance at 280 nm. 
U-
15
N and U-
15
N,
13
C-labeled Spider Roll I58A was expressed in M9 minimal media 
containing 
15
N-ammonium chloride (1 g/l). Glucose was replaced with 
13
C-glucose for 
13
C 
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labeling. Cells were grown in LB broth upto OD600 0.6 to 0.8 and then spun down by 
centrifugation at 3000 rpm for 30 mins. The cell pellet was then resuspended in M9 minimal 
media, left for recovery for 20 mins under 250 rpm shaking and then induced with 0.3 mM 
IPTG. The expression was carried at 16 °C for 14 h.  
Fluorescence polarization assay 
Binding affinity was measured using fluorescence polarization technique established in our 
laboratory.
37
 In brief thiol-reactive fluorescent probe Bodipy(507/545)-iodoacetamide 
(Molecular Probes) was conjugated to design variants at the unique cysteine site. Design 
variants at a concentration range of 60-250 µM were buffer exchanged into 50 mM Tris-Cl, 
pH 7.5 using a PD10 desalting column (GE Healthcare) and spiked with 1 mM TCEP. A 20 
mM stock solution of Bodipy(507/545-IA) suspended in dimethyl sulfoxide (DMSO)  was 
added drop-by-drop to 3-10 fold molar excess  in the designed variants with constant mixing 
by inverting the tubes. The tubes were wrapped with aluminium foil and conjugation reaction 
carried for overnight at 4 °C. Next morning β-mercaptoethanol (BME) to a final 
concentration of 50 mM was added to quench the reaction. The  mix was then centrifuged to 
pellet the unconjugated Bodipy and run over PD10 desalting column (equilibrated with 50 
mM Tris-Cl, pH 7.5 and 5 mM BME)  to separate the conjugated design variants from free 
Bodipy. Bodipy labeled design variants were quantified using UV/Vis spectrophotometer 
(theoretical molar extinction coefficient at 280 nm for protein and molar extinction 
coefficient of 69,000 M
-1
cm
-1 
for the probe). A correction factor (Abs280 nm/Abs508 nm) of 0.03 
was used to correct for the absorption of the conjugated probe at 280 nm. Typically probe 
conjugation efficiency (probe/protein) of 20-90 % was achieved for the design variants. 
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Fluorescence polarization assays were carried out on a Jobin Yvon Horiba Spex 
FluoroLog-3 instrument (Jobin Yvon Inc) performed in L-format with the excitation 
wavelength set at 508 nm and emission wavelength set at 545 nm. Bodipy-design variants (in 
50 mM Tris-Cl, pH 7.5, 5 mM BME) at a final concentration of 5-10 µM and volume 180 µl 
were titrated with PAK1-fl or PAK1variants (in 50 mM Tris-Cl, pH 7.5, 50 mM NaCl, 5 mM 
BME). Titrations were performed in 3×3-mm quartz cuvette. Slit width was adjusted to 3.5 
nm to give a fluorescence intensity ~3.5 million counts per second. Two polarization 
readings consisting of 3 averaged measurements were collected for at least 15 concentrations 
of titrant. Data were averaged and any change in polarization occurring due to addition of 
buffer was subtracted. Data was then analyzed using a model for single site binding model 
according to the equation (1) which was incorporated in equation (2) to account for the 
observed polarization.  
   (1) 
         (2) 
where [A:B] is the concentration of Bodipy labeled design variants and titrant (PAK1-fl or 
PAK1 variants) complex formed, [At] is the total concentration of Bodipy labeled design 
variants, [Bt] is the concentration of the titrant, Kd is the dissociation constant for the 
interaction, P0 is the polarization in the absence of titrant, Pmax is the maximum polarization 
observed when all Bodipy  labeled design variants are bound to the titrant, and Pobs is the 
observed polarization at a given concentration of titrant. The data were fit according to 
equation (2) using non-linear regression with SigmaPlot software to obtain fitted parameters 
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for Kd, Pmax and P0. Delta polarization (ΔPolarization) was calculated using equation (3) and 
fraction bound was calculated using equation (4). 
𝛥𝑃𝑜𝑙𝑎𝑟𝑖𝑧𝑎𝑡𝑖𝑜𝑛 = 𝑃𝑜𝑏𝑠 −  𝑃𝑚𝑖𝑛         (3) 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 =
𝑃𝑜𝑏𝑠 −𝑃𝑚𝑖𝑛
𝑃𝑚𝑎𝑥 −𝑃𝑚𝑖𝑛
         (4)                                          
where Pmax and Pmin are maximum and minimum polarization calculated from the fit. Mutants 
where Pobs
 
was much lower than possible Pmax, fit was forced to have Pmax observed in the fit 
of Spider Roll-PAK1 interaction (green circles in Figure 3.5). Inability to achieve titrants in 
very high concentrations put limitations on reaching the saturation level (>10-fold than Kd) 
during a single titration. 
NMR spectroscopy 
As Spider Roll I58A mutant expressed at more than 2-fold higher yield when compared with 
Spider Roll and since the I58A mutation had a minimal effect on the binding affinity (Figure 
3.5 b), we prepared U-
15
N and U-
15
N, 
13
C-labeled NMR samples of Spider Roll I58A.  
For assignment of polypeptide backbone and 
13
Cβ chemical shifts, NMR spectra were 
recorded at 288 K on a Varian INOVA 600 spectrometer equipped with a cryogenic probe. 
2D-[
15
N, 
1
H] HSQC (1 h measurement time) was acquired along with four through-bond 
correlated NMR experiments
21
 that is, HNCA (36 h), HN(CO)CA (36 h), HNCACB (42 h),  
CACB(CO)NH (42 h) and HNCO (9 h) for sequential resonance assignment.  In addition, a 
3D 
15
N-resolved [
1
H, 
1
H] NOESY spectrum (42 hours) was acquired to confirm sequential 
resonance assignments and to derive backbone 
1
HN-
1
HN distance constraints. All spectra 
were processed and analyzed using the program packages NMRPipe
38
 and XEASY
39
, 
respectively. Specifically, the titration of Spider Roll with PAK1 was monitored by recording 
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2D-[
15
N, 
1
H] HSQC spectra at 288 K on a Varian INOVA-700 MHz spectrophotometer 
equipped with a cryogenic probe. Isotope labeled proteins and kinase domain were buffer 
exchanged in 20 mM Phosphate buffer, pH 7.0, 50 mM NaCl and 1 mM DTT and 10% D2O 
was added. Peak volumes and line-widths in 2D-[
15
N, 
1
H] HSQC were measured by using the 
‘peak detection module’ of NMRDraw in NMRPipe. Signal-to-noise ratios (SNR) were 
calculated by dividing the volume by the noise level measured by the ‘estimate noise 
module’ of NMRpipe followed by division by the square root of the measurement time. To 
compare peak volume reductions arising from different degrees of Spider Roll-PAK1 
complex formation, the thus obtained SNR per unit time was normalized to the volume 
measured in the absence of PAK1.  
Chemical shifts were deposited in the BioMagResBank (accession code: 16710).
40
 
Circular dichroism (CD) 
CD data were collected on a Jasco J-815 CD spectrometer. Far-UV CD scans (250-195 nm) 
were carried at a typical protein concentration of 20 µM in a 1 mm cuvette. The temperature 
was maintained at 20 C̊ using a Peltier device. Variable temperature scan was carried 
between 4-96  ̊C while measuring the ellipticity at 222 nm. All ellipticity data were corrected 
with a buffer blank and then converted to mean residue ellipticity. 
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Supplementary figure S3.1. Structural characterization of Spider Roll and mutant 
scaffold (HYP, PDB ID: 1I2T). (a) Far-UV CD spectrum of 20 µM of Spider Roll 
compared with the CD spectra of HYP with mutations A15C/G26E/L37E/L38N. (b) CD 
signal at 222 nm as a function of temperature shows cooperative thermal denaturation. A 
significant difference in melting temperature (Tm) between Spider Roll and HYP is observed.  
The other designs tested showed similar spectra and cooperative thermal denaturation with 
differences in Tm and steepness in the slope. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure S3.2. Correlation between the predicted buried surface area and 
Rosetta binding energy for 43 native complexes (Supplementary table S1). Ten 
trajectories of DDMI were run to score the near native conformations. The conformation with 
the lowest binding energy was plotted here against the buried surface area. 
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Supplementary figure S3.3. 2D-[
1
H, 
15
N]-HSQC spectra of Spider Roll I58A and 
backbone resonance assignment. A 600 MHz 
1
H-
15
N spectrum of SpiderRoll I58A protein 
in (20 mM Phosphate, pH 7.0, 50 mM NaCl, 1 mM DTT, 8% D2O), obtained at 288 K.  
Backbone resonance assignments are labeled.  Side chain amides of Asn and Gln are 
connected by lines. No attempt was made to assign side chain peaks of Asn and Gln residues. 
Gly6 and Gly56 are folded due to the narrow spectral width of nitrogen dimension. 
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Supplementary figure S3.4. Comparison of secondary structures determined by 
chemical shift index (CSI, in blue), CS-Rosetta (in green) and X-ray (in red).  For 
residues which have no CSI output due to lack of assignments, are labeled as ‘×’.  
 
   
Supplementary figure S3.5. CS-rosetta structure prediction of Spider Roll I58A in an 
unbound state (green). Crystal structure of scaffold ‘HYP’ (PDB code: 1I2T) (red) and 
computational model Spider Roll (cyan) are also shown for comparison.  
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Supplementary figure S3.6. 2D-[
1
H, 
15
N]-HSQC spectra of Spider Roll with PAK1 or 
PAK1 L470E. (left) 148 µM Spider Roll I58A with 487 µM  PAK1; (right) 150 µM  
Spider Roll I58A with 490 µM PAK1 L470E mutant. The comparison illustrates that peak 
volume reduction is significantly less with kinase L470E. The data suggest that mutant 
interacts with Spider Roll with considerably weaker affinity. The marked residues underwent  
maximal change in the presence of PAK1. 
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Supplementary table S3.1. High resolution PDBs used for evaluation of DDMI protocol 
PDB 
Resolution 
(Å) Partner A / B 
1A4Y 2.0 Ribonuclease inhibitor / Angiogenin 
1AVA 1.9 Barley alpha-amylase / Barley alpha  amylase (Subtilisin) inhibitor 
1AY7 1.7 Guanyl-specific ribonuclease Sa / Barstar 
1BLX 1.9 Cyclin-dependant kinase 6CDK6 / P19ink4D 
1BRS 2.0 Barnase / Barstar 
1CLV 2.0 Alpha-amylase / Alpha-amylase inhibitor 
1CSE 1.2 Subtilisin  carlsberg / Eglin C 
1CXZ 2.2 Human RhoA /  Protein kinase PKN 
1D5M 2.0 Enterotoxin type B / HLA Class II Histocompatibility antigen 
1DPJ 1.8 Proteinase A / Proteinase inhibitor IA3 peptide 
1EAY 2.0 CheY/ CheY Binding (P2) Domain 
1EMV 1.7 Colicin E9 DNase/ Immunity protein IM9 
1EUV 1.6 ULP1 Protease / Ubiquitin like protein SMT3 
1F60 1.6 Elongation factor eEF1A / Exchange factor eEF1B alpha 
1FQK 2.3 RGS domain / GT-GI1 chimera unit 
1G4U 2.3 Protein Tyrosine phosphatase SPTP / Ras-related C3 Botulinum Toxin substrate 1 
1GCQ 1.68 VAV SH3 domain / Growth factor Receptor-Bound protein 2 SH3 domain 
1GL4 2.0 Nidogen 1 / PERLECAN IG3 
1HE1 2.0 GAP domain of Exoenzyme S / Ras-related C3 Botulinum Toxin substrate 1 
1HX1 1.9 HSC70 ATPase domain / BAG-family Molecular Chaperone Regulator-1 
1IAR 2.3 Interleukin4/Interleukin 4 receptor  alpha 
1IBR 2.3 GTP binding nuclear protein Ran/Importin Beta-1 subunit 
1IM3 2.2 HLA class I histocompatibility antigen A2 / Cytomegalovirus Protein US2 
1IQ5 1.8 Calmodulin / Calmodulin dependent kinase kinase 
1JDH 1.9 Beta catenin / hTcf-4 
1JIW 1.74 Alkaline Mettaloproteinase/ Alkaline Proteinase Inhibitor 
1JLT 1.4 Phospholipase A2/ Phospholipase A2 Inhibitor 
1JTP 1.9 Vh domain fragment of single domain antibody/ Lysozyme C 
1PPF 1.8 Human Leukocyte ELastase / Turkey Ovomucoid Inhibitor 
1QMZ 2.2 CDK2/ G2 mytotic-specific cyclin A 
1SGP 1.4 Streptomyces griseus proteinase B / Turkey Ovomucoid inhibitor 
1SVX 2.24 Ankyrin repeat  protein/ MBP 
1TX4 1.6 p50 RhoGAP/RhoA 
1U0S 1.9 CheA/CheY 
1UGH 1.9 Uracil DNA Glycosylase/UDG-Inhibitor 
1UJZ 2.1 Designed Colicin E7 Dnase/ Designed Colicin E7 Immunity Protein 
1YCS 2.2 p53/ 53BP2 
2B5R 1.65 Beta lactamase TEM/ Beta lactamase inhibitor protein 
2BKK 2.15 Ankyrin Repeat/ Amino Glycoside phosphotransferase 
2PCC 2.3 ISO-1-Cytochrome C/ Cytochrome C Peroxidase 
2SIC 1.8 Subtilisin BPN' / Streptomyces  Subtilisin Inhibitor 
4SGB 2.1 Serine Proteinase B / Potato Inhibitor 
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7CEI 2.3 Inhibitor IM7 protein / Endonuclease Domain of Colicin E7 
   
 
Supplementary table S3.2. Backbone assignment of Spider Roll I58A at 288 K.  
Residue 
15
N 
1
HN 13C 13C 
H1   57.76 30.29 
R2 120.66 8.46 58.87 30.26 
Q3 119.27 8.18 58.35 28.30 
A4 122.94 8.13 54.40 18.09 
L5 119.62 8.18 57.78 41.69 
G6 124.42 8.62 48.10 0.0 
E7 119.46 7.85 58.59 29.74 
R8 117.07 7.41 57.89 31.54 
L9 119.44 8.34 57.19 44.07 
Q14   59.39 29.52 
C15 117.66 8.43 57.17 40.26 
K23 123.58 7.99 58.42 32.33 
I24 117.52 8.64 64.74 37.94 
T25 116.74 8.21 68.68 69.50 
E26 118.41 7.67 59.78 29.40 
M27 117.80 7.74 58.95 33.20 
L28 120.87 8.54 57.12 40.64 
L29 115.62 7.74 56.18 40.98 
E30 116.14 7.25 56.49 29.81 
L31 120.56 7.80 54.58 41.64 
S32 114.89 8.49 56.75 62.88 
P33   66.01 31.47 
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A34 117.98 8.19 55.00 18.25 
Q35 118.49 7.79 58.54 29.01 
L36 121.22 8.53 58.07 42.20 
E37 118.00 8.44 59.30 28.80 
N38 117.50 7.47 56.22 38.26 
L39 119.12 7.99 57.41 41.12 
L40 115.54 7.85 56.18 41.48 
A41 119.89 7.40 52.56 19.62 
S42 112.71 7.46 55.37 63.26 
E43 123.44 8.23 63.52  
D44   57.24 44.25 
S45 118.68 8.48 62.34 53.30 
L46 123.59 8.29 58.62 39.71 
R47 119.34 8.70 60.04 29.85 
D48 118.81 7.81 57.22 40.00 
Q49 118.38 7.93 57.97 27.64 
V50 122.05 8.83 67.17 31.29 
R51 120.31 7.94 59.78 29.41 
Y52 119.94 8.09 60.07 37.38 
A53 123.36 8.39 54.76 18.30 
M54 115.77 8.30 56.45 31.55 
A55 121.37 7.59 53.95 17.83 
G56 122.69 7.71 45.63  
I57 121.13 7.69 62.77 38.54 
A58 124.16 8.02 52.56 18.55 
F59 118.86 7.87 58.16 39.48 
H60 120.41 8.10 55.35 29.89 
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G61 115.65 7.58 45.92  
 
Supplementary table  S3.3. Length and composition comparison of the secondary 
structure elements between X-ray structure and CS-Rosetta structure 
X-ray structure (1I2T) CS-Rosetta structure 
Residue 
Number 
Residue 
name 
Secondary 
structure 
Residue 
Number 
Residue 
name 
Secondary 
structure 
   -1 GLY Turn 
   0 SER helix I 
1009 HIS turn 1 HIS helix I 
1010 ARG helix I 2 ARG helix I 
1011 GLN helix I 3 GLN helix I 
1012 ALA helix I 4 ALA helix I 
1013 LEU helix I 5 LEU helix I 
1014 GLY helix I 6 GLY helix I 
1015 GLU helix I 7 GLU helix I 
1016 ARG helix I 8 ARG helix I 
1017 LEU helix I 9 LEU helix I 
1018 TYR helix I 10 TYR helix I 
1019 PRO helix I 11 PRO helix I 
1020 ARG helix I 12 ARG helix I 
1021 VAL helix I 13 VAL helix I 
1022 GLN helix I 14 GLN helix I 
1023 ALA helix I 15 CYS Bend 
1024 MET helix I 16 MET Bend 
1025 GLN turn 17 GLN Turn 
1026 PRO helix II 18 PRO helix II 
1027 ALA helix II 19 ALA helix II 
1028 PHE helix II 20 PHE helix II 
1029 ALA helix II 21 ALA helix II 
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1030 SER helix II 22 SER helix II 
1031 LYS helix II 23 LYS helix II 
1032 ILE helix II 24 ILE helix II 
1033 THR helix II 25 THR helix II 
1034 GLY helix II 26 GLU helix II 
1035 MET helix II 27 MET helix II 
1036 LEU helix II 28 LEU helix II 
1037 LEU helix II 29 LEU Turn 
1038 GLU turn 30 GLU Turn 
1039 LEU bend 31 LEU Bend 
1040 SER turn 32 SER Turn 
1041 PRO helix III 33 PRO helix III 
1042 ALA helix III 34 ALA helix III 
1043 GLN helix III 35 GLN helix III 
1044 LEU helix III 36 LEU helix III 
1045 LEU helix III 37 GLU helix III 
1046 LEU helix III 38 ASN helix III 
1047 LEU helix III 39 LEU helix III 
1048 LEU helix III 40 LEU helix III 
1049 ALA helix III 41 ALA helix III 
1050 SER turn 42 SER Turn 
1051 GLU helix IV 43 GLU helix IV 
1052 ASP helix IV 44 ASP helix IV 
1053 SER helix IV 45 SER helix IV 
1054 LEU helix IV 46 LEU helix IV 
1055 ARG helix IV 47 ARG helix IV 
1056 ALA helix IV 48 ASP helix IV 
1057 ARG helix IV 49 GLN helix IV 
1058 VAL helix IV 50 VAL helix IV 
1059 ASP helix IV 51 ARG helix IV 
1060 GLU helix IV 52 TYR helix IV 
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1061 ALA helix IV 53 ALA helix IV 
1062 MET helix IV 54 MET helix IV 
1063 GLU helix IV 55 ALA helix IV 
1064 LEU helix IV 56 GLY helix IV 
1065 ILE helix IV 57 ILE helix IV 
1066 ILE helix IV 58 ALA coil 
1067 ALA helix IV    
1068 HIS helix IV    
1069 GLY coil    
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CHAPTER 4 
DESIGN OF A METAL-MEDIATED PROTEIN-PROTEIN 
INTERACTION 
Abstract 
Metal-mediated protein-protein interactions (PPIs) have several advantages over interactions 
lacking metal. The most prominent is the enthalpic gain, as metal coordination is stronger 
than the non-covalent interactions that exist between amino acids. The other advantage is that 
metal sites at protein interfaces can help align the two partners for a useful PPI and hence 
contribute significantly to the association rate. Keeping these things in mind we attempted a 
metal-mediated de novo protein interface design with a more physiologically relevant 
binding affinity. Three zinc-coordinating residues were designed on ‘scaffold’ proteins, the 
fourth coordination contributed by a naturally occurring exposed histidine side-chain (HisT) 
on the ‘target’ protein (UbC12 /Ubiquitin). Conformational sampling was achieved by   
rotating around the Zn-HisT coordination bond and by varying the dihedral angles of HisT. 
Using this 3×1 approach (3 coordinating residues on the ‘scaffold’ and 1 on the ‘target’), a 
computationally designed protein ‘Spelter’ was created from the bacterial flageller hook-
filament junction protein (PDB ID: 2D4X) to interact with ubiquitin as the ‘target’. The 
success was modest as Spelter showed tight binding with Zn
2+
 ion but did not show visible 
Zn-mediated interaction with Ubiquitin.  
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Introduction 
Metal ions are indispensable for cellular activities. One-third of all protein structures in the 
protein data bank (PDB) contain a protein-bound metal ion. These metal ions have both 
structural as well as catalytic roles to play. One of the most important metal ions is zinc (Zn
2+
 
referred to as Zn from here onwards). Zn is the only metal represented in all classes of 
enzymes.
1
 Zn is predominantly 4-coordinated (tetrahedral geometry) for structural role while 
for catalytic role 5- and 6-coordinations are also observed.
2
  The geometrical properties of 
both catalytic and structural Zn are related to very subtle differences in the coordinate bond 
length and angles that determine the geometry. The residues that most prominently interact 
with Zn are His and Cys but Asp and Glu are also seen to play both structural and catalytic 
roles. One major difference between structural and catalytic Zn sites is the ligand preference. 
For structural roles, Zn is often coordinated to two or more Cys, while in case of catalytic 
sites, His is the major ligand as it helps Zn to be a better electron acceptor and serve as a 
Lewis acid.
2
 
 A Zn atom site serving a structural role would be an energetic advantage for the 
protein-protein interface. One of the main contributions comes from huge enthalpy gain from 
a coordinate bond formed between Zn and ligand atom. These metal-ligand bonds are 
stronger than other non-covalent bonds formed at the interface. A Zn binding motif at the 
protein-protein interface has also shown to improve the association rate.
3
 For example, a non-
native Zn binding motif consisting of four ligands was created at the interface of hGH-
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hPRLR (human growth hormone – human prolactin receptor). Two ligands from each side of 
the interface contributed to the Zn coordination.  Zn binding only influenced the on-rate of 
the two proteins confirming that Zn coordination is orientation specific and can contribute to 
the alignment of the two proteins that interact. The guiding effect of having a Zn site on a 
protein interface seems to be same as having a knob-hole combination at the interface. 
There have also been recent successes with metal-directed self assembly.
4; 5; 6
 Using a 
four helix bundle protein, Cytochrome cb562 as a model, Salgado et al were able to create a 
Zn-dependent tetramer of the protein by engineering two dihistidine motifs at the N- and C-
termini of the protein.
4
 The monomeric protein had many polar surface residues and the huge 
interface created by self association was unfavorable due to burial of these polar groups. Zn 
mediated interactions at the interface was thought to provide enough thermodynamic driving 
force to favor the formation of tetrameric assembly. In a subsequent study, the group showed 
that how a small number of metal coordinating mutations on a non-self-associating protein 
can help overcome the entropic cost of association and promote the optimization of other 
non-covalent interactions to form more stable architecture which can form even in the 
absence of metal.
5
 The authors went on to suggest their results could have evolutionary 
implications.  
  The Achilles’ heel of metal-mediated interface design is to find the right position for 
creating a metal binding motif. The challenge is to simultaneously find a position for the Zn-
binding motif and create a large buried surface area that is designable. For the previous 
works of metal-mediated self-assembly of cytochrome cb562, the crystal packing interactions 
were chosen as the starting point for creating metal-interacting motifs and for optimization of 
non-covalent interactions around them.
5; 6
 In case of hetero-assembly, where two different 
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proteins are involved in metal-mediated interaction, it becomes more challenging to find two 
different proteins with a designable crystal packing interface. Apart from that, a metal 
binding motif across the interface requires designing both sides of the protein interface. An 
immediate advantage of this approach would be to create orthogonal binding partners of 
already interacting partners, very similar to a knob-in-to-hole approach which was used to 
design orthogonal pairs of GoLoco peptide and Gαi1.
7
 Alternatively, a 3×1 approach might 
allow one to find a naturally occurring single ligand on an undersigned target.  
In our effort to create a Zn-mediated interaction, we chose to go for 3×1 approach 
where 3 Zn coordinating residues were designed on the ‘scaffold’ protein and the last one 
contributed by the chosen target protein. We hypothesized that it was more common to find a 
single Zn-ligand at the surface of a protein than having two Zn-ligands capable of 
simultaneously coordinating a Zn. Zn-mediated protein interface was created three steps: first 
designing three residues on the ‘scaffold’ protein and then placing the fourth ligand from the 
‘target’ at the right orientation with respect to Zn, then rigid-body searching for orientations 
with compatible surfaces at the interface. At the end the ‘scaffold’ protein was optimized for 
hydrophobic and polar interactions with the ‘target’. 
Results 
Model proteins for Zn-mediated de novo design 
The criterion for a good ‘target’ protein was to have an exposed His around some potentially 
hydrophobic residues so that a complementary binding interface can be created on the 
‘scaffold’ protein. Ubiquitin has an exposed His at position 68 (H68), with V70, I44 and L8 
in close proximity to it. I44 in Ubiquitin has been recognized as a ‘hotspot’ residue for 
protein-protein interaction.
8; 9
 Similarly UbC12 (a NEDD8-conjugating enzyme) has an 
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exposed His at position 88 (H88) which corresponds to the position F63 in UbCH7 (Figure 
4.1). F63 in UbCH7 is a key residue in interaction with the HECT domain of E6AP (PDB ID: 
1C4Z).
10
 Since these histidines are surrounded by residues known for protein-protein 
interactions, they are good ‘targets’ for this design strategy. 
 
 
 
 
 
 
 
 
 
Figure 4.1. Selected ‘target’ proteins for Zn-mediated de novo interface design. (a) 
Ubiquitin (PDB ID: 1UBQ) shows L8, V70 and I44 residues that involved in protein-protein 
interaction. Residue H68 (circled) was used as ‘target’ His for Zn-coordination with a 3×1 
approach. (b) UbC12 (PDB ID: 1Y8X) showing the exposed His88 that was used for Zn 
coordination. (c) UbCH7-HECT domain interface (PDB ID: 1C4Z) showing the F63, residue 
corresponding to H88 in UbC12 (yellow) at the interface against HECT domain (magenta). 
Multiple ‘scaffold’ proteins were considered for the de novo interface design. The 
main criteria for selecting a ‘scaffold’ protein from PDB database was high resolution crystal 
structure, monomeric, expressible in  E. coli, absence of disulphide bonds, below 70% 
sequence identity from any other ‘scaffold’ and of length 80-250 residues. A total of 636 
scaffolds were selected (Supplementary table S4.1). 
Design protocol 
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A three-step design strategy was used for the 3×1 approach of Zn-mediated protein interface 
design. In the first step, RosettaMatch
11
 was used to find three Zn ligand positions on all 
‘scaffold’ proteins. RosettaMatch was developed earlier for designing novel enzymes.12; 13 It 
uses a transition state model (TS) to search for designable residue sets on a ‘scaffold’ protein 
that might stabilize the TS and catalyze a reaction. In our case, the TS consisted of a HisT 
(histidine from ‘target’) positioned at a right distance and orientation with a Zn atom that is 
consistent with Zn-coordination geometry (Table 4.1, Figure 4.2). To search for ligand 
triplets, His/Cys rotamers were placed at all surface positions of the ‘scaffold’ and the TS 
was placed sequentially. The ensemble of TS positions satisfying the scoring criteria was 
recorded in a hash table. The hash table was then scanned for overlapping TS positions that 
satisfied tetrahedral geometry with protein side-chain ligands at the three open Zn-
coordination positions. The output file (match) of RosettaMatch protocol consisted of atomic 
coordinates of these three positions on the ‘scaffold’ plus the TS model.  The matches were 
then filtered for redundancy and quality of geometry based on the sum of squared differences 
from ideality of the four co-ordinate bond lengths, six tetrahedral angles and dihedral angle 
(χ3) that determines the planarity of imidazole ring of His with respect to coordinated Zn. A 
total of ~1000 good matches were found on 636 ‘scaffold’ protein surfaces. 
Table 4.1. Tetrahedral geometry parameters for Zn-coordination. The numbers indicate 
the mean values with standard deviation of parameters observed in protein database.
2; 11
 The 
numbers were used for imposing constraints during the RosettaMatch search. 
 Atom pair d (Å) θ1 (
o
) θ2 (
o
) χ1 χ2 χ3 (
o
) 
His Zn…N 2.05±0.15 109±15 120±15 Free Free 0/180 (±15)
a 
Cys Zn…S 2.33±0.10 109±15 109±15 Free Free Free 
a
: Determines the coplanarity of Zn and the imidazole ring in His residues. 0
o 
is compatible 
for Zn…Nδ and 180
o
 is compatible for Zn…Nε.  
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Figure 4.2. Tetrahedral geometry parameters for Zn-coordination. TS used for 
RosettaMatch was HisT-Zn shown in grey color (Zn in grey sphere). The residues in green 
are other ligands (His and Cys) that complete the tetrahedral geometry. The black (bold) line 
is the distance parameter. The dotted lines represent angles θ1 (tetrahedral angle) and θ2. χ1, χ2 
and χ3 are the dihedral angles shown in arrows. χ3 determines the coplanarity of the His 
imidazole ring and the Zn. 
In the second step, TS His replaced the ‘target’ His bringing the Zn, ‘target’ and 
‘scaffold’ together. The initial conformation represents the RosettaMatch TS-binding 
conformation grafted into the ‘target’ and ‘scaffold’ and is guaranteed to have a reasonable 
metal site but not necessarily a complementary interface. A rigid-body conformational search 
was achieved by rotating the ‘target’ around the Zn-N vector between metal ion and ‘target’ 
His or by changing the side-chain dihedral angles of His to new angles consistent with 
Dunbrack rotamers
14
 (Figure 4.3). Any move was accepted or rejected based on Metropolis-
Monte Carlo criteria while optimizing the low-resolution centroid score function.
15
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Figure 4.3. Rigid-body conformational search for Zn-mediated interface design between 
‘target’ (yellow) and ‘scaffold’ (cyan) proteins. Rotation around the Zn-N vector and 
changing the two dihedral angles of the HisT side chain resulted in large changes in rigid-
body orientations between the two proteins without disrupting the metal site.  
After a specified number of these moves (typically 100 to converge), an all-atom 
energy function
15
 was optimized using mutations while accepting or rejecting a move based 
on Monte Carlo. During the design process, the residues on the two sides of interface that 
coordinated with Zn were kept fixed and the residues on the scaffold were mutated to any 
other residue (except Cys) and repacked with side chain minimization. The residues on the 
‘target’ were repacked and side chain minimized while keeping the sequence fixed. 
Selection criteria of Zn-mediated interface designs 
The final selection of the designs was based on the quality of Zn-coordination geometry and 
the interface design quality. The binding energy density (binding energy / buried surface 
area) (which excluded the contribution from the Zn coordination), number of unsatisfied 
hydrogen bonding groups and total number of mutations made in the ‘scaffold’were all 
considered. In all cases lower number was favored. Six designs were selected for 
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experiments from as many as 250,000 independent trajectories. The designs with various 
parametric scores used for selection are shown in Table 4.2. Two designs used an ankyrin 
repeat protein (PDB ID: 1SVX) as a scaffold, one design used the N-terminal half of 
Archaeloglobus fulgidus xeroderma pigmentous groups B helicase (PDB ID: 2FZ4) as a 
‘scaffold’, one design was based on Plasmodium falciparum ubiquitin conjugating enzyme 
(PDB ID: 2ONU) and remaining two designs were based on a fragment from bacterial 
flagellar hook-filament junction (PDB ID: 2D4X) as ‘scaffold’. A representative design 
model is shown in Figure 4.4. 
 
 
 
 
 
 
 
 
 
Figure 4.4. Computational model of Zn-mediated interaction between Ubiquitin and a 
designed ‘scaffold’. Ubiquitin (yellow) shows H68 coordinating with Zn and I44 very close 
to a Trp designed on a scaffold, 2D4X (cyan). Arg-Asp salt bridge is another important 
interaction in this design. The designed ‘scaffold’ was named Spelter. 
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Experimental characterization and binding assays with selected designs 
The six designs were expressed as 6×His tagged MBP fusion proteins. 2ONU_ubq design 
(where 2ONU stands for the ‘scaffold’ and ubq for the Ubiquitin ‘target’) aggregated as soon 
as it was cleaved from the 6×His-MBP protein and was not further characterized. The two 
designs based on ankyrin repeat (Ank_UbC12_0032 and Ank_UbC12_0097) aggregated in 
the presence of Zn. 2FZ4_ubq also showed aggregation upon addition of Zn. Other groups 
have also observed the phenomenon of metal-mediated protein oligomerization and 
aggregate formation.
16
 The two designs derived from 2D4X scaffold (2D4X_ubq_0028 or 
Spelter and 2D4X_ubq_0320) remained soluble when cleaved from 6×His-MBP tag. Note 
that only Ubiquitin-targeting designs were characterized beyond this point. 
 The binding interactions between the ‘target’ protein, Ubiquitin and the 2D4X-based 
designs were measured using isothermal titration calorimetry (ITC) and fluorescence 
polarization (FP) assays. In case of ITC, Ubiquitin (Sigma) in a buffer having Zn was titrated 
into either Spelter or 2D4X_ubq_0320 preloaded with same concentration of Zn. In the FP 
assay, Bodipy-labeled ubiquitin was titrated with 2D4X-based designs and change in 
polarization measured. In both kinds of experiments no change in signal observed, 
confirming that Ubiquitin might not be binding with 2D4X-based designs at all. 
Zn binding capability of the designs 
After finding no metal-mediated Ubiquitin binding, Spelter was used to test whether the 
designed protein was indeed binding Zn. In order to find the Zn binding affinity of Spelter, 
ITC experiments were done where Zn was titrated into Spelter. The experiment showed a 
very tight binding (Kd ~9.5 nM) with a molar ratio of ~1 (Figure 4.5 a). In order to further 
confirm that the metal is binding at the right site, the two cysteines were reverted back to the 
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wild-type residues (Spelter_noCys). In an ITC experiment with Spelter_noCys, Zn titration 
did not show any appreciable heat released or absorbed (Figure 4.5 b).  
 
 
 
 
 
 
 
  
 
Figure 4.5. Isotheraml titration calorimetry (ITC) assays to show Zn binding to Spelter. 
(a) 20 µM Spelter was titrated with 250 µM ZnSO4. The titration shows low nanomolar 
binding. (b) Spelter_noCys (where designed cysteines were reverted back to WT residues) 
did not show any appreciable change in heat during ITC titrations where 20 µM 
Spelter_noCys was titrated with 250 µM ZnSO4. 
A complementary thermal denaturation CD experiment was done with Spelter in the 
presence and absence of Zn. We hypothesized that binding of metal would stabilize the 
protein causing an increase in thermal melting temperature (Tm). A far-UV CD scan showed 
Spelter was helical, consistent with the crystal structure of the scaffold (Supplementary 
figure S2.1). Thermal denaturation at 222 nm showed cooperative denaturation curve with 
Tm ~45 ̊C (Figure 4.6 a). When denaturation was carried at a protein:Zn molar ratio of 1:1, 
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Tm increased to ~52 C̊. Further increasing the amount of Zn (protein: Zn = 1:10) resulted in 
higher Tm (~ 55 C̊). Apart from the increase in Tm, Zn also caused increased cooperativity 
during thermal denaturation. The effect of Zn on thermal denaturation of protein was not 
observed for Spelter_noCys (Figure 4.6 b). 
 
 
 
 
 
Figure 4.6. Circular dichroism signal at 222 nm as a function of temperature in the 
presence and absence of Zn. (a) 15 µM Spelter was used without ZnSO4 and with 
Spelter:Zn molar ratio of 1:1 and 1:10. Addition of Zn increased the Tm and cooperative 
nature of denaturation. (b) 15 µM Spelter_noCys was used. Addition of Zn did not show any 
measurable effect on Tm and unfolding cooperativity. 
Discussions 
This work shows very modest success in designing metal-mediated protein-protein 
interactions. The challenge in this work was twofold, designing a Zn-binding motif and then 
creating a Zn-mediated heterodimer. Using RosettaMatch the first hurdle was successfully 
overcome. Spelter, which had three out of four residues designed onto its fixed-backbone 
showed a low nanomolar binding to Zn. However, most of the designs aggregated as soon as 
Zn was added to the protein solution.  
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Table 4.2. Computational scores of the design models based on which selections were 
made. 
Design Scaffold Target Interface 
size (Å
2
) 
Binding 
energy 
density 
(REU/ Å
2
)
a 
# of 
unsatisfied 
polar groups 
SASApack 
score 
Ank_UbC12_0032 1SVX UbC12 1564 -0.011 5 0.73 
Ank_UbC12_0097 1SVX UbC12 1478 -0.012 2 0.58 
2FZ4_ubq 2FZ4 Ubq 1704 -0.009 1 -0.48 
2ONU_ubq 2ONU Ubq 1459 -0.009 5 0.05 
2D4X_ubq_0028 
(Spelter) 
2D4X Ubq 1231 -0.012 4 -0.315 
2D4X_ubq_0320 2D4X Ubq 1302 -0.012 4 -1.12 
a
:The binding energy does not include the contribution from the metal site. 
A protein will typically have many potential Zn-coordinating residues on its surface and a 
designed Zn-binding motif can assist oligomerization. Hence, it seems likely that a Zn-
binding motif was created in those cases too: one that bound zinc between monomers. 
 The failure to show formation of a Zn-mediated heterodimer could have resulted due 
to the limited enthalpic contribution in the 3×1 approach where only one coordinating bond 
bridges the interface. To test affinity for a potential ligand at the fourth site, in an ITC 
experiment, several Zn-binding ligands (2-mercaptoethanol, DTT, pyridine or imidazole) 
were titrated into Spelter saturated with Zn. The ligands failed to show any binding in those 
experiments. When Zn coordinates with three residues on Spelter, the fourth ligand is likely 
to be solvent water to complete the tetrahedral geometry. So when ligands like 2-
mercaptoethanol, DTT, pyridine or imidazole were titrated to Spelter, they had to compete 
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with 55 M of water. A 2×2 approach where both ‘target’ and ‘scaffold’ contribute equally to 
Zn-coordination could have more enthalpic contribution across the interface. 
 There is also a scope of improving the search of conformational space. Backbone 
minimization during the design was missing in the present protocol. The search space can be 
also improved by relaxing the geometric parameters (θ2 and d of the Zn-N vector) using the 
standard deviation values (Figure 4.2, Table 4.1). 
 Overall the work still shows encouraging result as far as a rational design of a ligand 
binder is concerned. A recent publication showed that computational design of a ligand 
binder is still an unsolved problem.
17
 In an effort to design a Zn-mediated heterodimer, the 
present work shows a successful design of a metal binding protein. 
Material and methods 
Computational design of Zn binding motifs 
Zn binding motifs were designed using RosettaMatch
11
 which has been developed for 
enzyme design and is a part of Rosetta molecular modeling program.
15; 18
 A detailed 
description of RosettaMatch method can be found elsewhere.
11; 12
 In summary, for each 
scaffold first all the designable positions were identified. The residues which had less than 18 
neighboring residues at a cutoff distance of 5.5 Å were considered surface residues and 
designable positions. All Dunbrack rotamers
14
 of His/Cys were enumerated at each position. 
The placement was rejected if the side-chain clashes with the protein backbone. A transition 
state model (TS, the term is a reminiscent from the computational enzyme design for which 
RosettaMatch was created) consisting of a HisT and a Zn atom (Figure 4.2) was placed near 
each rotamer so that two of the four sites for a tetrahedral geometry were satisfied. The 
position of the TS was then recorded in a hash table. The hash table was then examined for 
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TS positions that were compatible with precalculated rotamer positions in combinations of 
three such that no two rotamers originated from the same sequence position. An output file 
‘match’ consisted of TS coordinates and coordinates of three His/Cys rotamers (with 
sequence position on the ‘scaffold’) that completed the tetrahedral geometry of a Zn binding 
motif. 
De novo interface design around a Zn-binding motif 
A ‘match’ consisted of 4 residues (HisT-Zn and 3 ligands with position numbers from the 
‘scaffold’). A starting structure was created where 3 ligands were grafted at the specified 
positions on the ‘scaffold’ and the ‘target’ histidine (H68 on ubiquitin or H88 on UbC12) 
was aligned with HisT while maintaining the relative orientation of Zn. Huge backbone 
clashes between the two proteins were common after this stage. Next, the interface design 
process was done in two stages. In the first stage, a rigid body search in centroid mode was 
done to identify conformations that relieved the backbone clashes and gave good surface 
complementarity. The rigid-body search was done by randomly rotating the ‘target’ protein 
around the HisT-Zn vector or by changing the two dihedral angles of the side chain. After 
each move the centroid energy score
15
 was  calculated and the move was accepted or rejected 
based on the Metropolis criterion.  A ‘Dual Monte Carlo’ approach was used during which 
the centroid coordinates (centroid pose) as well as all-atom coordinates (all-atom pose) were 
tracked and stored simultaneously. This allowed Rosetta to maintain fully atomic details of 
the metal site while scoring based on less-sensitive centroids. Typically 100 rigid body 
moves resulted in a convergence. During the second stage, the all-atom pose was designed 
and repacked on the ‘scaffold’ side while only repacking the ‘target’ side. All rotamers 
(except Cys) was used for the ‘scaffold’ while for the ‘target’, only rotamers of the native 
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residues were considered. The design process consisted of Monte-Carlo moves where the all-
atom energy function
15
 was used to accept or reject moves based on the Metropolis criterion. 
After the design/repack stage side-chains were also minimized using gradient descent to 
nearest local minimum.
15
  
Binding parameters calculation    
The method has been discussed in chapter 3. 
Experimental methods 
Plasmid constructs 
 The ‘target’ genes (ubiquitin and UbC12) were cloned in an in-house vector derived from 
pQE-80L where a DNA sequence of MBP (maltose binding protein) was added in the 5’ end 
of the gene. The genes for all design variants were synthesized in-house using overlapping 
oligos.
19
 The codons used were optimal for bacterial expression. 
Expression and protein purification 
The method has been described in detail in chapters 2 and 3. Protein expression was done in 
BL21(DE3) pLysS cells. The expressed proteins with 6×His-MBP fusion were purified using 
a prepacked Ni-NTA column (HisTrap, HP, GE Healthcare). Post cleavage using TEV 
protease, protein samples were loaded again on same Ni-NTA column and flow through 
collected. The flow through was concentrated (Amicon Ultra, Millipore) and loaded on a size 
exclusion column (Superdex 75, GE Healthcare) equilibrated and eluted with MOPS buffer 
(10 mM MOPS, pH 6.9, 25 mM NaCl and 0.5 mM TCEP).  
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Isothermal titration calorimetry 
Binding affinities were measured using VP-ITC isothermal titration calorimeter (MicroCal, 
GE Healthcare). For measuring the ubiquitin binding affinity of Spelter, commercially 
available ubiquitin (Sigma Aldrich) at a concentration of 250 µM in MOPS buffer 
supplemented with 800 µM ZnSO4 was titrated in 20 µM Spelter in the same buffer. For 
measuring the Zn binding affinity of Spelter, 250 µM of ZnSO4 in MOPS buffer was titrated 
in 20 µM Spelter exhaustively dialysed in the same buffer.   To test Zn-mediated ligand (2-
mercaptoethanol, DTT, pyridine, imidazole) binding, a stock of 250 µM ligand was titrated 
into 20 µM Spelter. A total of 29 titrations of 10 µl each were made. The data were analyzed 
using Origin50 software and fitted using a model for ‘one-site binding’. 
Fluorescence polarization assay 
A detailed method for labeling proteins with thiol-reactive fluorescent probe 
Bodipy(507/545)-iodoacetamide (Molecular Probes) has been discussed in chapters 3 and 4. 
In ubiquitin, position 28 (Ala) was mutated to Cys to enable labeling with Bodipy probe. 
UbC12 already has Cys at positions 47, 65, 95, 111 and 181 of which C65 and C111 are 
exposed and can be labeled with Bodipy probe. Conjugation efficiency was typically very 
low (5%-10%) which may be due to poor positioning of the site. The experiment was carried 
in MOPS buffer with 800 µM of ZnSO4. 
Circular dichroism (CD) experiments 
CD data were collected on a Jasco J-815 CD spectrometer. Far-UV CD scans (260-195 nm) 
were carried at a typical protein concentration of 15µM in MOPS buffer in a 1 mm cuvette . 
The temperature was maintained at 20 C̊ using a Peltier device. A variable temperature scan 
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was carried out between 4-96 ̊C while measuring the ellipticity at 222 nm. ZnSO4 at final 
concentration of 15 µM or 150 µM was added wherever appropriate. All ellipticity data were 
corrected with a buffer blank and then converted to mean residue ellipticity. 
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Supplementary information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure S4.1. Far –UV CD scan of Spelter and mutant Spelter as a 
function of Zn concentration. The scan shows no effect of Zn on secondary structure 
content of the protein. 
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Supplementary table S4.1. List of scaffolds used for Zn-mediated de novo interface 
design 
 
1a58 1a7s 1aky 1aly 1c81 1cke 1e58 1e5k 1e9m 1ex7 1f4p 1f9y  
1fdr 1fm4 1g2r 1g8a 1gmi 1gmx 1gnu 1gwm 1h0p 1h1d 1h68 1h6h 
1h7c 1hbk 1he9 1hh8 1hqv 1htj 1hxi 1i1n 1i2a 1i39 1i5g 1i76 
1i8a 1iap 1id0 1ifr 1ijt 1ikt 1im5 1imj 1io2 1ipc 1iqz 1iu9 
1iuh 1iuk 1ixv 1j2a 1j3a 1j84 1jbe 1jf8 1jg1 1jhs 1jjv 1jl1 
 1jmw 1jos 1jrl 1juv 1jvw 1jwq 1k1b 1k6k 1k7j 1kgs 1kmq 1kmv 
1kon 1kr7 1ksk 1kw4 1ky3 1kzf 1kzl 1l2h 1l3k 1lb4 1lfp 1lm6 
1lqy 1lu4 1lvg 1m2k 1mb3 1mg4 1mij 1mj4 1mk0 1mqo 1mr3 1mve 
1mvo 1n3y 1nb9 1neg 1nh9 1nio 1nnx 1nqz 1nwz 1nzn 1o08 1o1z 
1o4r 1o6d 1o8v 1o8x 1o9g 1oap 1ocs 1od3 1oh4 1ojq 1opd 1osh 
1p2f 1p4p 1p4x 1p5f 1p5s 1p90 1pa7 1paq 1pbk 1pi1 1pko 1pmh 
1pz4 1q1u 1q7h 1q7r 1q8b 1qcy 1qf9 1qv1 1qwz 1qzm 1r18 1r26 
1r2d 1r2q 1r6j 1r6n 1r9h 1r9w 1rkb 1rlj 1rm8 1roc 1rw1 1rw7 
1rwj 1ryb 1rz3 1rz4 1s1e 1s21 1s29 1s2o 1s2x 1s35 1s3g 1s3p 
1s68 1s69 1s7z 1s8n 1s9u 1sau 1sbx 1svx 1sdi 1sen 1sgw 1sh6 
1sqw 1su0 1svi 1t00 1t3y 1t4w 1t95 1ta0 1tev 1tff 1tke 1tov 
1tq3 1tq5 1tqh 1ts9 1tt8 1ttz 1tuh 1tuv 1tyj 1u02 1u2p 1u3g 
1u61 1u6t 1u7o 1u7u 1u84 1u9c 1u9p 1uhn 1ui0 1ujc 1ulr 1umh 
1unq 1uoh 1uow 1upq 1urr 1ux8 1uxx 1uy4 1uyl 1uz0 1v0a 1v5h 
1v77 1v7r 1vaj 1ve4 1vg1 1vjf 1vjk 1vjx 1vk1 1vk2 1vkb 1vkk 
1vku 1vmb 1vr3 1vr8 1vsr 1vyf 1vzw 1w0h 1w0n 1w1d 1w24 1w2l 
1w41 1w4s 1w66 1w8g 1w9w 1wbe 1wd5 1wj9 1wjx 1wl8 1wlf 1wlj 
1woj 1wpa 1wqg 1wr2 1wri 1wrm 1ws0 1ws6 1wu3 1wub 1wv3 1wvh 
1wvn 1wzw 1x0t 1x1r 1x3o 1x6o 1x6z 1x8h 1xbi 1xbn 1xbs 1xcl 
1xdz 1xe1 1xj3 1xk5 1xkr 1xmt 1xs5 1xt0 1xtq 1xw3 1xww 1y02 
1y63 1y6i 1y81 1y88 1y8c 1y93 1y9q 1yd0 1ye8 1yio 1yn4 1yqb 
1ysp 1ysq 1yul 1yvd 1yzl 1z06 1z0f 1z0i 1z0w 1z1s 1z2a 1z2m 
1z2u 1z3x 1z4r 1z67 1z6g 1z95 1zat 1zd8 1zd9 1zde 1zi8 1zma 
1zn6 1zv9 1zzk 1zzo 2a0j 2a1i 2a1v 2a2k 2a4v 2a5j 2a7b 2a7m 
2a8e 2a90 2a9o 2aak 2aan 2af0 2aj6 2amh 2amy 2ap3 2ar1 2ar5 
2atz 2avk 2avr 2awg 2awk 2azw 2b0c 2b5h 2bbr 2bdv 2bep 2bf0 
2bfw 2bh4 2bk8 2bk9 2bkf 2bl1 2bl7 2bl9 2bm3 2bmd 2bmm 2bmv 
2boo 2brf 2bsn 2bwq 2byo 2bz7 2bzg 2c1f 2c2p 2c3g 2c53 2c60 
2c71 2cal 2cb9 2cbz 2cdn 2ce2 2cfe 2chd 2cjj 2ckk 2ckx 2cm5 
2cmt 2cu9 2cul 2cwr 2cws 2cwy 2cx1 2cxh 2cxv 2cy2 2cyj 2cyy 
2d1e 2d2e 2d3d 2d3y 2d4x 2d58 2d6o 2dch 2dho 2djh 2dwr 2e1f 
2e6m 2ei9 2esa 2esb 2etd 2etj 2eve 2ew0 2ew1 2ew5 2exu 2eyi 
2f1w 2f21 2f9l 2fcf 2fck 2fcl 2fdj 2fdr 2fe5 2ff7 2ffq 2fgo 
2fi1 2fiw 2fj9 2fl7 2fm9 2fn4 2fq3 2fsq 2fsx 2fu2 2fuf 2fuk 
2fup 2fvv 2fwh 2fyg 2fz4 2g3r 2g3y 2g6b 2g7b 2g9f 2gbn 2gf9 
2gkg 2gkp 2go2 2gu3 2gui 2gw2 2gwm 2gwr 2h17 2h5p 2haz 2hb5 
2hbw 2hcf 2hcu 2hdo 2hdz 2he4 2hhz 2hia 2hje 2hnx 2hp7 2hpj 
2hpk 2hqk 2hs5 2hsb 2hw4 2hwv 2hxm 2hxp 2hzc 2i0m 2i5h 2i5u 
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2i6c 2i6j 2i6v 2i88 2i9c 2i9w 2ia7 2iaf 2iay 2ibb 2ibj 2ici 
2idv 2igp 2ihd 2ije 2il1 2il5 2img 2in3 2ior 2ipq 2iqc 2is9 
2iu1 2iug 2iwd 2iwn 2iyv 2j13 2j1a 2j1l 2j22 2j44 2j49 2j5a 
2j6a 2j8k 2j9v 2jc7 2jd9 2jdc 2jek 2jex 2jfr 2jg6 2jhs 2jin 
2nly 2nn5 2nn8 2nq3 2nqw 2nr3 2nr9 2ns0 2ns6 2nsq 2nsz 2nyv 
2o2g 2o2x 2o37 2o71 2o7a 2o9u 2oc5 2ocs 2odh 2odv 2ofz 2ogq 
2oj4 2olm 2oml 2onu 2opc 2oqk 2oqz 2oss 2ot9 2ovj 2ozf 2p0d 
2p0t 2p2e 2p3h 2p57 2p8g 2pa1 2pag 2pc1 2pcs 2pe8 2phc 2pkt 
2pl1 2pl3 2plu 2plw 2pnm 2pny 2poe 2poi 2ppx 2pv4 2pwq 2pww 
2pxx 2q0v 2q3h 2q7b 2q9v 2qg1 2qgg 2qgu 2qjl 2v0s 2v1l 3eug 
Table 4.2. Amino acid sequence of the designs tested. 
Design Amino acid sequence 
Ank_UbC12_0032 
SDLGRKLLEAARAGQDDEVRILMANGADVNAADKWGTTPLHLAAKSGHLEIVE
VLLKHGADVDASDAMGYTPLHWAALMGHLEIVEVLLKNGADVNAMDNHGCT
PLCLAAHAGYLEIVEVLLKHGADVNAQDKFGKTAFDASIDNGNEDLAEILQKL 
Ank_UbC12_0097 
SDLGRKLLEAARAGQDDEVRILMANGADVNAADKWGTTPLHLAAKSGHLEIVE
VLLKHGADVDASDAMGYTPLHWAALMGHLEIVEVLLKNGADVNAMDNHGCT
PLCLAAHAGYLEIVEVLLKHGADVNAQDKFGKTAFDASIDNGNEDLAEILQKL 
2FZ4_ubq 
IAEIYYERGTIVVKGDAHVPFAKFDSRSGTYRAKAHWYREIIEYFESNGIEFVDNA
ADPIPTPYFDAEISLRDYQERMLEYWLIYKWSCVLLPTGSGKTHVAMAAINELST
PTLIVVPTLALAEQWKERLGIFGEEYVGEFSGRIKELKPLTVSTYDSAYVNAEKL
GNRFMLLIFDGDGGLASTSWWQILEMSIAPFVLCLHADNE 
2ONU_ubq 
SLSRLQCDFTKLIMAGYDLRLINNHTIVFLVMFHGPNGTAYEGGIWMVFVALPW
QFPQRSPHICFMNKLLHPNVHEDTGCVKEDVINQTWTPLYSLVNVFEVFLPQLLT
DPNPSDPLNSDAASLLMKDKNIYEEKVKEYVKLYASKDLWE 
2D4X_ubq_0028 
(Spelter) 
VVLSQAQAQNSQYALARTFATQKVSLEESVLSQVTTAIQTAQEKIVYAGNGTLS
DDDRASLATDLQGIRDQLMNLANSTDGNGRYIFAGYKTEAAPFDQATGGYHGG
EKSVTQQVDSAITLEIGHTGAQIFNSICECAVPEPDGSDSEKNLFVMLDTAIAALK
TPVEGNNVEKEKAAAAIDKTNRGLKNSLHNVLEVRWELEWFLELLSAKDGE 
2D4X_ubq_0320 
VVLSQAQAQNSQYALARTFATQKVSLEESVLSQVTTAIQTAQEKIVYAGNGTLS
DDDRASLATDLQGIRDQLMNLANSTDGNGRYIFAGYKTEAAPFDQATGGYHGG
EKSVTQQVDSAETMVIGHTGAQIFNSICGCAVPEPDGSDSEKNLFVMLDTAIAAL
KTPVEGNNVEKEKAAAAIDKTNRGLKNSLHNVLFVRWMLGRQLDDLSTLDSL 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
Computational protein design offers a huge challenge in identifying a sequence compatible for a 
given tertiary structure. The problem becomes more difficult if the backbone is also unknown for 
the design of a sequence. The problem is addressed by a flexible backbone design approach 
which iterates between lowest energy sequence prediction for a fixed backbone and lowest 
energy backbone prediction for a fixed sequence to come up with a minimum energy sequence 
for a structure. Another challenge in computational protein design is de novo design of a protein 
interface on a given protein structure for protein-protein interactions. 
Redesign of PAK1 auto-inhibitory domain for a biosensor 
We used iterative sequence and backbone optimization protocols for redesigning the auto-
inhibitory domain (AID) of PAK1 into an affinity reagent. The new secondary structure 
sequences ranged from 3 residues for a β-hairpin for the design Hairpin to a 20 residue helical 
sequence for the design AlmostHelix. The goal was to stabilize the AID by building upon the 
protein core and hence improve the tertiary structure. Our effort to improve the tertiary structure 
was also done in conjunction with improving the binding affinity of the affinity reagent since the 
simplest one; WT_IS (residues 83-137) was unfolded and bound with an affinity of only 4 µM. 
The idea was that a more structured affinity reagent would have lower entropy cost for folding 
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upon binding and would show tighter affinity. Different approaches but a similar goal were used 
to come up with three generations of designs, Hairpin, AlmostHelix and PAcKer. 
AlmostHelix showed improvement in secondary and tertiary structure but there was no 
improvement in binding affinity for the PAK1 kinase domain. We concluded that the increase in 
‘rigidity’ might have ‘locked’ the binding interface on AlmostHelix in a perturbed conformation. 
All our effort to crystallize AlmostHelix in an unbound state was not successful because the 
domain still was not too folded to attain an ordered structure. The chemical shift peaks of 2D-
[
15
N, 
1
H] HSQC of AlmostHelix did not show very well-spread amide peaks confirming that the 
designed protein did not have a well-defined tertiary structure. 
A designed 16-residue helix in the C-terminus of PAcKer did not show any structural 
advantage over WT_IS. The actual core of WT_IS is between residues 87-128 (number based on 
PDB ID: 1F3M). The new sequence in the C-terminus made a minimal interaction with the other 
core residues. What was huge advantage in PAcKer was that the N- and C-termini were brought 
close to each other, making its insertion in fluorescent proteins (between residues E172 and 
D173) with ease. CFP-PAcKer bound with a ten-fold improvement in binding affinity to the 
PAK1 kinase domain. The insertion into a CFP protein where N- and C-termini were constrained 
in space was analogous to the wild-type AID where the N- and C-termini are constrained by a β-
strand swap and peptide-domain interaction (residues 143-146 of AID and the kinase domain) 
respectively.  
CFP-PAcKer when conjugated with a solvent-sensitive dye works as a biosensor in vitro. 
In future directions, CFP-PAcKer still has a scope of improvement. Long range electrostatic 
interactions between the newly designed helix and the domain trunc-WT_IS-2 (residues 87-137) 
can be established by mutating neutral residues to charged residues. The proposed mutations will 
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also help improve the solubility of the affinity reagent. A dye conjugated affinity reagent often 
aggregate when microinjected in cells. Preliminary experiments where CFP-PAcKer derived 
biosensor was microinjected in cells, showed signs of aggregation at the tip of the needle or 
inside the cells. 
Post purification all WT_IS derived designs (except AlmostHelix) showed signs of 
proteolysis. PAcKer as well as CFP-PAcKer showed proteolysis. Apart from the new sequences 
added on in AlmostHelix (at N-terminus) and PAcKer (on C-terminus) the major difference is an 
inclusion of residues 87-99 (of wild-type sequence based on PDB ID: 1F3M) in PAcKer. These 
residues can be probed more for proteolysis. Some other works from a different group have 
indicated the range between residues 105 to 118 to be more susceptible to proteolytic cleavage.
1
 
Ultimately the focus is to use the biosensor derived from CFP-PAcKer in vivo. The 
specificity and sensitivity issues will be clearer only after that and will provide more 
opportunities for improvement of the biosensor. 
De novo design of a PAK1 binder 
For de novo interface design work, we had a modest success in designing specific binders. We 
developed a DDMI protocol, which uses rigid-body docking, sequence design, and gradient-
based minimization of backbone and side chain torsion angles to design low energy interfaces 
between a ‘scaffold’ and a ‘target’ protein. Using that protocol, from scratch we designed an 
interface on a ‘scaffold’ protein, hyperplastic disc protein (PDB ID: 1I2T). The designed protein, 
Spider Roll bound with a dissociation constant of 100 µM to the kinase domain of PAK1. The 
binding affinity we achieved had low physiological relevance; we think that there were several 
feats which we achieved. 
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Spider Roll is a first computational one-sided design. One-sided protein designs have 
applications as protein therapeutics and affinity   reagents for   biosensors. Our approach needs 
only structural information of the ‘target’ with biochemical information which identifies residues 
on the ‘target’ involved in protein-protein interaction.  
We have incorporated docking, design and backbone side chain minimization in our 
protocol. DDMI can be assumed to do what nature does for designing an interaction between a 
‘scaffold’ protein and a ‘target’.  Dock stage in our protocol recapitulates nature’s effort to 
search for complimentary surfaces and burial of potential ‘hotspot’ residues on the target. Design 
stage of DDMI protocol, recapitulates nature’s effort in coming up with mutations on ‘scaffold’ 
that can potentially get rid of unwanted steric clashes, and produce useful interactions in the form 
of hydrogen bonds and salt bridges. Lastly minimization stage recapitulates nature’s induced-fit 
mechanism and allostery which results in subtle to larger backbone and side chain movements. 
We believe nature also has to go through a number of iterations of design and minimization to 
come up with a physiologically relevant interaction. 
Our ability to create an alternative binding protein or an affibody for a biologically 
important protein PAK1 is also an achievement. PAK1 plays role in plethora of functions, 
ranging from cytoskeletal motility to signal transduction, to apoptosis to cell cycle progression 
and has shown to be involved in pathological condition and transformation.
2
  Some recent 
reviews have already warranted us with a need for novel engineered protein scaffolds and novel 
binding protein from nonimmunoglobulin domains.
3; 4
 Spider Roll was designed from a 
nonimmunoglobulin domain which does not have any documented biological relevance with 
PAK1.  
125 
The final notable feat is Spider Roll’s ability to distinguish between a fully active form of 
PAK1 and ‘closed’ inactive form of PAK1. This will have an important application as an affinity 
reagent for a biosensor that can be utilized to visualize spatio-temporal dynamics of the activate 
form of PAK1. 
Despite the above feats, we think that we failed in creating a physiologically relevant 
binding affinity or an affinity that has potential application as therapeutics or affinity reagents. 
Our best binder Spider Roll still lagged behind most of the binding affinities of the native 
complexes (in Table 3.1) by 3-5 orders of magnitude or even greater. The Rosetta scores for our 
designed models could be distinguished from the scores of the native complexes in several areas. 
First the binding interfaces of the native complexes were distinctly larger than our designed 
interfaces. Our protocol failed to create/select large interfaces partially due to the nature of the 
‘target’ interface and due to the stringency in rejecting higher number of unsatisfied polar groups 
at the interface. Secondly the native interfaces were much more polar than designed interfaces. 
There is a tradeoff between hydrogen bonding energy and the solvation penalty. An approximate 
nature of energy function fails to predict it correctly. Lastly the interfaces were overall poorly 
packed than the native complexes. The drawback of our DDMI protocol is that the packing 
quality solely depends on the L-J interaction, which likes to bring the atoms close but avoid any 
overlap. ‘Clumping’ of atoms can occur in computational designs, where individual atom pairs 
are more closely spaced than crystal structure.
5
  
Another huge setback observed was in terms of the solubility of the de novo designs. 
Since we were targeting a hydrophobic patch on PAK1, we expected the designed interface to be 
hydrophobic. The resulting increase in propensity to aggregate was not recovered by other 
mutations distant from the interface in some of our designs. A need to introduce solubility score 
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in the energy function or during the selection criteria will help reduce the failures and give more 
opportunities test the computational ability to design a novel interaction. 
We also lacked in our focus to work on the association rates of two interacting proteins. 
NMR studies with Spider Roll and PAK1 confirmed that association rate of the binding was 
much lower than 10
5 
M
-1
s
-1
. The on-rate constants for protein-protein binding can vary 
dramatically (1×10
3
 M
-1
 s
-1
 to 1×10
9
 M
-1
 s
-1
) but are often near 1×10
6
 M
-1
 s
-1
.
 6; 7 
Achieving shape 
complementarity helps improve the association rate and by choosing a ‘scaffold’ with good 
structural homology with a natural binder (AID) of PAK1, we addressed the requirement. 
Another approach is to identify charged residues near the ‘hotspot’ region on the ‘target’ and 
design oppositely charged residues on the ‘scaffold’.  
Metal-mediated protein-protein interactions can also have improved association rates
8
 
due to the ‘guiding’ effect to metal site (very similar to knob-hole combination). As a part of 
future directions of ‘de novo protein interface design’ we attempted to design a Zn-mediated 
interaction. The design, Spelter, selected from a 3×1 approach (one Zn-coordinating ligand from 
the ‘target’ and another three ligands designed on the ‘scaffold’) for metal-mediated interface 
design showed no evidence of metal-mediated protein-protein interaction though metal-binding 
was established. 
Overall the successes in this work can be overshadowed by the failures. Understanding 
the failures can be as important in the learning processes. The knowledge from the experiments 
and adequately addressing the failures can help improve the reliability of computational protein 
design. 
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